





ANTIMICROBIAL RESISTANCE PREVENTION AND CONTAINMENT STRATEGIC PLAN THE ONE HEALTH APPROACH

2021–2025 Third edition










ANTIMICROBIAL RESISTANCE PREVENTION AND CONTAINMENT STRATEGIC PLAN THE ONE HEALTH APPROACH

2021–2025 THIRD EDITION



May 2021 Addis Ababa ,Ethiopia

TABLE OF CONTENT

| FOREWORD | i |
|---|------|
| MESSAGE FROM AMR PREVENTION AND CONTAINMENT ADVISORY COMMITTEE | ii |
| ACKNOWLEDGEMENTS | iii |
| ABBREVIATIONS | iv |
| EXECUTIVE SUMMARY | V |
| KEY CONCEPTS AND DEFINITIONS | vii |
| VISION, MISSION, GOAL AND SCOPE | viii |
| 1. BACKGROUND | 1 |
| 1.1 Country profile | 2 |
| 1.2 Antimicrobial resistance overview | 4 |
| 2. RATIONALE FOR REVISIONS IN THIRD STRATEGIC PLAN | 18 |
| 3. STRATEGIC PLAN | 19 |
| 3.1 Objective one: Improve awareness and understanding of antimicrobial resistance through effective behaviour change communication, education and training | 21 |
| 3.2 Objective two: Strengthen the knowledge and evidence on antimicrobial use and resistance through surveillance and research | 23 |
| 3.3 Objective three: Enhance infection prevention and control through effective environmental health, infection prevention and bio-risk management in human, animal and plant health care | 25 |
| 3.4 Objective four: Optimize the use of antimicrobials in human, animal and plant health care | 27 |
| 3.5 Objective five: Strengthen and establish partnerships, alliances, governance and resource mobilization at all levels | 30 |
| 4. OPERATIONAL PLAN | 32 |
| 5. MONITORING AND EVALUATION FRAMEWORK | 67 |
| 5.1 Monitoring and evaluation plan | 70 |
| 5.2 Key performance indicators | 71 |
| 6. RISKS AND MITIGATION | 76 |
| REFERENCES | 78 |
| ANNEX TERMS OF REFERENCES FOR ANTIMICROBIAL RESISTANCE MULTISECTOR GOVERNANCE STRUCTURE | 81 |

TABLES

| Table 1 Analysis of the strengths, weaknesses, opportunities and threats regarding antimicrobial resistance prevention and control | 9 |
|--|----|
| Table 2 Stakeholder analysis for antimicrobial resistance prevention and containment | 11 |
| Table 3 Critical issues and core enablers related to antimicrobial resistance | 17 |
| Table 4 Initiatives and interventions for objective one Table 5 Initiatives and interventions for objective two | 22 |
| Table 5: Initiatives and interventions for objective two | 24 |
| Table 6 Initiatives and strategic interventions for objective three | 26 |
| Table 7 Initiatives and strategic interventions for objective four | 28 |
| Table 8 Initiatives and strategic interventions for objective five | 31 |
| Table 9 Detailed operational plan for objective one | 33 |
| Table 10 Detailed operational plan for objective two | 39 |
| Table 11 Detailed operational plan for objective three | 48 |
| Table 12 Detailed operational plan for objective four | 56 |
| Table 13 Detailed operational plan for objective five | 64 |
| Table 14 Monitoring and evaluation operation plan | 70 |
| Table 15 Key performance indicators | 71 |
| FIGURES | |
| Figure 1 Antimicrobial resistance governance framework | 8 |
| Figure 2. Strategic Objectives of National AMR Strategic Plan | 20 |
| Figure 3. Strategic Initiatives for Awarness and Education Strategic Objective | 21 |
| Figure 4. Strategic Initiatives for IPC and Hygiene Strategic Objective. | 25 |
| Figure 5. Core Elements of Anti-Microbial Stewardship | 27 |
| Figure 6 Logic model for the National Antimicrobial Resistance Prevention and Containment Strategic Plan | 69 |

FOREWORD







There is global consensus on the profound threat that antimicrobial resistance poses to human and animal health. The global health community recognized the urgency of this crisis in 2015 when it adopted the World Health Organization's Global Action Plan on Antimicrobial Resistance.

After realizing widespread and emerging antimicrobial resistance and the grave consequences on the country's health, economy and security, the Government of Ethiopia joined the global community in seeking to better understand and disable the threat. The Government launched in 2011 a National Strategy for the Prevention and Containment of Antimicrobial Resistance, followed by a second strategy for 2015–2020 that integrated the One Health approach. Various efforts followed each edition.

This third iteration of the national Antimicrobial Resistance Prevention and Containment Strategic Plan, for 2021–2025, sharpens the One Health approach to target the large amount of work still to be done. It integrates recent national and global updates and reflects the best available local evidence, stakeholders' concerns and inputs, the socioeconomic and sociocultural context of Ethiopia and the components of the country's health system. This third strategic plan defines the role of all implementing stakeholders and shall be the focus for investments into antimicrobial resistance prevention and containment efforts in Ethiopia.

We want to express our sincere appreciation to all the stakeholders and development partners whose immense contribution and support made the development of this third strategic plan possible despite the COVID-19 pandemic situation.

Because antimicrobial resistance is one of the challenges of our time, fighting this threat is a priority that requires a collaborative approach across sectors. We call upon all stakeholders for continued, coordinated and effective support for achieving the goals and priority objectives of the strategic plan.

We would like to assure you of our commitment to promote, facilitate, finance and monitor the effective implementation of the national strategic plan and achievement of the strategic objectives.

Dr Lia Tadesse

Hon. Minister Ministry of Health Dr. Fikru Regasa

Hon. State Minister Ministry of Agriculture Prof. Fekadu Beyene

Hon. Commissioner

Environment, Forest and Climate Change Commission



MESSAGE FROM AMR PREVENTION AND CONTAINMENT ADVISORY COMMITTEE

One of the major breakthroughs in the history of humankind was the discovery of antimicrobials. Considered "miracle drugs", they changed the health of human beings. Their use in animal husbandry and veterinary medicine also has resulted in healthier and more productive farm animals, thus ensuring the welfare and health of both animals and humans.

Unfortunately, from the first use of penicillin, resistance emerged. Sir Alexander Fleming recognized its deadly potential early on. Yet, antimicrobial resistance was denied proper attention until recent times. It gained concern over the past two decades, reaching public health crisis in the past few years for its impact on health as well as economies. The issue is multidimensional and requires collaboration among many stakeholders to overcome. Thus, Ethiopia created the multisector National Antimicrobial Resistance Advisory Committee in 2008. It has many appreciable results to its credit. But the country has a long way to go to prevent and contain the antimicrobial resistance threats.

The Government has put in place a framework with this strategic plan to address the threats that antimicrobial resistance poses to the welfare of the people and livestock of Ethiopia. The strategic plan sets out a coordinated and collaborative One Health approach involving key stakeholders in government and other sectors. The National Antimicrobial Resistance Advisory Committee will continue to coordinate the work to be done and monitor the progress. The Government also will continue to work with other governments, international organizations and partners to counter this global public health crisis.

The objectives of the strategic plan can only be successful through the continued political commitment, collaboration and concerted effort of all stakeholders. I hope that our collaboration with communities, civil society organizations, development partners, donors, academics, associations and the private sector will continue to strengthen the antimicrobial resistance prevention and containment efforts. I am looking forward to working with you all towards the successful implementation of the Antimicrobial Resistance Prevention and Containment Strategic Plan and the realization of its vision.



Yakob Seman

Director General, Medical Services

Ministry of Health, Ethiopia

ACKNOWLEDGEMENTS

The development of the third strategic plan was possible through the contributions and support from the Ministry of Health, the Ministry of Agriculture, the Environment, Forest and Climate Change Commission and their agencies.

The AMR secretariat would like to thank the World Health Organization, the Food and Agriculture Organization of the United Nations and the Medicines, Technologies and Pharmaceutical Services Programme of the United States Agency for International Development (USAID/MTaPS) for their generous financial and technical support in the drafting of this third strategic plan.

We also acknowledge the National Antimicrobial Resistance Advisory Committee members and the USAID Global Health Supply Chain Program's Procurement and Supply Management for their significant technical support throughout the process.

Sincere appreciation is extended to the members of the third strategic plan revision task force, whose support was central during development of this strategic plan.

The strategic plan through different revision processes that included drafting, reviewing and enriching through consultative and validation workshops comprising the Ministry of Health, the Ministry of Agriculture, the Environmental, Forest and Climate Change Commission, professional associations, academia, partner organizations and facilities. We heartily thank all the individuals and organizations who participated and contributed to this third strategic plan revision process..

ABBREVIATIONS

| AHRI | Armauer Hansen Research Institute |
|--------|---|
| AISCO | Agricultural Inputs Supply Corporation |
| AMR | antimicrobial resistance |
| AWaRe | access, watch and reserve |
| BCC | behaviour change communication |
| CDC | Africa Centres for Disease Control and Prevention |
| EBI | Ethiopian Biodiversity Institute |
| EEFRI | Ethiopian Environment and Forest Research Institute |
| EFCCC | Environment, Forest and Climate Change Commission |
| EFDA | Ethiopian Food and Drug Authority |
| EIC | Ethiopian Investment Commission |
| EML | Essential Medicines List |
| EMLA | Ethiopian Medical Laboratory Association |
| EPHI | Ethiopian Public Health Institute |
| EPSA | Ethiopian Pharmaceutical Supply Agency |
| FAO | Food and Agriculture Organization of the United Nations |
| GDP | gross domestic product |
| GHSA | Global Health Security Agenda |
| GLASS | Global Antimicrobial Surveillance System |
| HIV | human immunodeficiency virus |
| HSTP | Health Sector Transformation Plan |
| MOA | Ministry of Agriculture |
| MOE | Ministry of Education |
| MOF | Ministry of Finance |
| МОН | Ministry of Health |
| MOSHE | Ministry of Science and Higher Education |
| MOTI | Ministry of Technology and Innovation |
| NAHDIC | National Animal Health, Diagnostic and Investigation Centre |
| NAMRAC | National Antimicrobial Resistance Advisory Committee |
| NAP | national action plan |
| NIMC | National Interministerial Committee |
| OIE | World Organisation for Animal Health |
| UNICEF | United Nations Children's Fund |
| USAID | United States Agency for International Development |
| VDFACA | Veterinary Drug and Feed Administration and Control Authority |
| WHO | World Health Organization |
| | |

EXECUTIVE SUMMARY

Antimicrobials are essential to medical care and public health. They are vital for reducing morbidity and mortality in individuals who present with microbial infections. Antimicrobials are also essential for the prevention and treatment of infectious diseases in veterinary practice and agriculture across the livestock industry, fisheries and crop production. Thus, they are important for the food production chain and national economies.

Antimicrobial medicines have saved millions of lives, substantially reduced the burden of diseases that were previously widespread, improved people's quality of life and helped increase life expectancy. At the same time, the emergence and spread of antimicrobial resistance in several microorganisms has rendered the management of many infectious diseases difficult. Antimicrobial resistance has become a principal public health problem of the twenty-first century. It threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi that are no longer susceptible to the common medicines used to treat them. Over several decades, to varying degrees, bacteria causing common or severe infections have developed resistance to each new antibiotic coming to market.

Faced with this reality, action to avert the evolving global crisis in health care is imperative.

Globally, antimicrobial resistance causes an estimated 700 000 deaths every year. Failing to tackle antimicrobial resistance could, by 2050, cause an estimated 10 million deaths a year and cost up to \$100 trillion. The highest impact likely will be in Asia and Africa, which likely will account for an estimated 4.7 million and 4.2 million deaths, respectively. In Ethiopia currently, misuse of antimicrobials is common among human and animal health care providers, unskilled and animal husbandry practitioners and drug users. Various studies reflect an alarming rate of antimicrobial resistance.

The prevention and containment of antimicrobial resistance has a common approach and requires integrated and well-coordinated efforts at the global, national, institutional and individual levels. The global community recognizes the urgency of this crisis. The Government of Ethiopia has joined the global community in seeking to better understand and curb antimicrobial resistance. In 2006, the Government established the National Antimicrobial Resistance Advisory Committee, followed by the first national strategy framework in 2011. The second Strategy for the Prevention and Containment of Antimicrobial Resistance, for 2015–2020, was launched in October 2015.

In that second strategy, Ethiopia embraced the One Health approach to overcome antimicrobial resistance through concerted, collaborative and integrated efforts across the human, animal, plant health, food, feed and environment sectors. The approaches primarily centre on water, sanitation, hygiene and wastewater management to prevent infection and contain pollution.

In 2017, the Government developed and approved its National Antimicrobial Resistance Surveillance Plan for laboratory-based antimicrobial resistance surveillance. The plan establishes a national surveillance network capable of detecting priority antimicrobial resistance pathogens, analysing and reporting data, characterizing resistance and generating evidence to inform the implementation of targeted prevention and control programmes. It is now (2019–2023) accompanied with an integrated National Antimicrobial Resistance and Residue Surveillance Plan for the animal health care, plant, food safety and environment sectors.

Although Ethiopia initiated antimicrobial resistance prevention and containment practices early and has followed through considerably, the Government fears the country remains behind in controlling the antimicrobial resistance threats and risks. This lagging is attributed to an inadequate multisector approach, insufficient and poor-quality antimicrobial resistance and antimicrobial data and use, lack of sustainable financing, suboptimal practices, inadequate number of trained professionals and insufficient laboratories and supplies.

To catch up with the threats and risks, the third national strategy on prevention and containment

of antimicrobial resistance needed several revisions. In addition to aligning with the World Health Organization's Global Action Plan on Antimicrobial Resistance, it must reflect the country's Growth and Transformation Plan for the health, agriculture and environment sectors. The next strategy for Ethiopia needed a better-articulated vision for protecting the human, animal and plant populations and the environment from the health as well as socioeconomic and environmental consequences of antimicrobial resistance. Yet, it must ensure continuity of the successful approaches already practised for the prevention, control and treatment of infectious diseases in humans, animals and plants through multisector collaboration.

The third edition of the national strategy responds to these requisites through the One Health approach and the following five strategic objectives.

- 1. Improve awareness and understanding of antimicrobial resistance through effective behaviour change communication, education and training.
- 2. Strengthen the knowledge and evidence on antimicrobial use and resistance through surveillance and research.
- 3. Enhance infection prevention and control through effective environmental health, infection prevention and bio-risk measures in human, animal and plant health.
- 4. Optimize the use of antimicrobials in human, animal and plant health care.
- 5. Strengthen and establish partnerships, alliances, governance and resource mobilization at all levels.

The third strategy is a product of a step-wise process, from development of the concept note and establishment of a task force to oversee the revision process to a series of reviews, consultations and validation and approval exercises. This third edition consists of 5 strategies, 22 initiatives, 66 interventions and 180 operational plans with costing and a monitoring and evaluation framework. The estimated budget amounts to \$22 794 540. Nearly two thirds (66%) of the budget is allocated for objective two (research and surveillance), followed by 13.1% for objective four (prudent use of antimicrobials) and 11.6% for objective one (awareness and education).

The National Antimicrobial Resistance Advisory Committee will coordinate implementation of this strategy and monitor the progress of interventions. Although its success will rely heavily on the Government's commitment, the private sector, civil society organizations and the general public have significant contributions to make by supporting the government efforts or implementing some of the proposed interventions.

KEY CONCEPTS AND DEFINITIONS

| One Health | Is a "whole of society" approach that recognizes that the health of people is connected to the health of animals and the environment. The goal of the One Health concept is to encourage multidisciplinary collaborative efforts across different sectors, such as health, agriculture and the environment, to achieve the best health outcomes for people and animals. |
|----------------------------------|--|
| Health care associated infection | Is acquired after contact with health care services. It most frequently occurs due to treatment in hospital but can also happen after treatment in outpatient clinics, nursing homes and other health care settings. Health care-associated infections that are picked up in hospital are also known as "hospital-acquired infections". Surgical site infection, pneumonia, urinary tract infection, bloodstream infection and gastroenteritis are the five most common hospital-acquired infections |
| Antimicrobial resistance | occurs when an antimicrobial that was previously effective is no longer operative to treat an infection or disease caused by a microorganism. Antimicrobials are medicines used to treat infections or disease and are essential in both human and animal health. The development of resistance is a natural phenomenon that will inevitably occur when antimicrobials are used to treat disease. The problem at present is that the sheer volume of antimicrobials being used globally in humans and animals is leading to significant increases in the rate of resistance, with the result that common infections are becoming more difficult to treat. And microor-ganisms that are resistant to many antimicrobials are emerging as the so-called "superbugs". |
| Antimicrobial stewardship | Is a systematic approach to optimizing antimicrobial therapy through a variety of structures and interventions. It includes limiting the inappropriate use of antibiotics and optimizing antimicrobial selection, dosing, route and duration of therapy to maximize clinical cure while limiting the unintended consequences, such as the emergence of resistance, adverse drug events and costs. |
| AWaRe list of antibiotics | ACCESS antibiotics that are first- and second-choice options for common infections and should be available in all countries and all facilities. WATCH for antibiotics that only should be prescribed for specific indications because they are at higher risk of bacterial resistance. RESERVE antibiotics, including last-resort options |

VISION, MISSION, GOAL AND SCOPE

Vision

To protect human, animal and plant populations and the environment from the health, socioeconomic and environmental consequences of antimicrobial resistance in Ethiopia.

Mission

To reduce the negative impacts of antimicrobial resistance through the generation and utilization of evidence, awareness and education on the prudent use of antimicrobials and the promotion of sectoral, national and global alliance and collaboration.

Goal

To ensure continuity of successful prevention, control and treatment of infectious diseases in the human, animal, plant and environment sectors through evidence-based prevention and containment of antimicrobial resistance following multisector collaboration through a One Health approach.

Scope

This third strategic plan covers improving awareness and understanding on antimicrobial resistance, preventing and controlling infections, strengthening the knowledge and evidence on antimicrobial resistance through surveillance and research, ensuring the prudent use of antimicrobials and the governance of antimicrobial resistance prevention and containment in human, animal and plant health care, food and feed production and the environment sectors at the national, regional and facility levels. The scope is also aligned with the Global Action Plan on Antimicrobial Resistance, the National Growth and Transformation Plan, the National Health Sector Transformation Plan II, the National Action Plan for Health Security and Animal Health Strategy, and the Vision for Ethiopia. This antimicrobial resistance strategy harmonizes with the National Healthcare Quality and Safety Strategy, the National Infection Prevention and Control Strategy and the standard treatment guidelines for general hospitals. In line with the Universal Declaration of Human Right, this strategic plan addresses vulnerable groups and the rights of people living with disabilities.

BACKGROUND

Country Profile



1.1 COUNTRY PROFILE

Geography and climate

Ethiopia is located in the north-eastern part of Africa, also known as the Horn of Africa. It is bordered by Sudan and South Sudan to the west, Eritrea and Djibouti to the north-east, Somalia to the east and south-east and Kenya to the south. Ethiopia has a national government system involving 10 regional states, 2 city administrations and 840 districts. The country occupies an area of 1.1 million square kilometres and has diverse climate and landscapes. The climate is generally divided into three zones: the alpine vegetated cool zones (Dega), at more than 2600 metres above sea level, where temperatures range from near freezing to 16°C; the temperate zones (Woina Dega), where much of the country's population is concentrated, with areas between 1500 and 2500 metres above sea level and temperatures ranging between 16°C and 30°C; and the hot zone (Qola), which encompasses both tropical and arid regions and has temperatures ranging between 27°C and 50°C.

Demographic profile

According to its Central Statistics Agency, Ethiopia is the second-most populous country in Africa and twelfth globally, with a population of about 104 million people in 2021. It is home to various ethnicities, with more than 80 spoken languages. The country is experiencing rapid population growth (at 2.6%), a young age structure and a high dependency ratio, with a high rural-urban differential. Ethiopia had one of the higher total fertility rates in Africa in 2016, at 4.6 births per woman (2.3 in urban areas and 5.2 in rural areas) and a corresponding crude birth rate of 32 per 1000 population. The average household size was 4.6 persons in 2013 (CSA, 2013).

Ethiopia has the largest livestock population in Africa. The national herd comprises 57 million cattle, 30 million sheep, 23 million goats and 57 million chickens as well as camels, horses and a small number of pigs (FAO, 2019).

Socioeconomic situation

Ethiopia is engaged in rapid and comprehensive development activities to transition from impoverished status to sustainable and reliable growth and prosperity. The country registered commendable achievements with the Millennium Development Goals, mainly in reducing the poverty head count, achieving universal primary education, narrowing gender disparities in primary education, reducing child and neonatal mortality and managing HIV, tuberculosis and malaria (FDRE, 2016).

Since 1991, the Government has worked to achieve economic transformation from an agricultural economy to an industrial-led economy. The World Bank classifies Ethiopia as a low-income country, with a gross domestic product (GDP) per capita of \$850 in 2019. The country has been one of the fastest-growing economies in Africa and aims to reach lower-middle-income status by 2025 (World Bank, 2019).

As much as 70% of the population keeps livestock. Livestock contribute an estimated 10% of total export earnings. It also contributes 21% of the national GDP and 49% of the agricultural GDP (FAO, 2019). However, the contribution of the livestock sector to the national economy is minimal when compared with its potential. One of the main causes of this mismatch between population size and production output from livestock in Ethiopia is the widespread occurrence of many infectious and parasitic diseases, which drastically reduce the production of livestock due to morbidity, mortality and market restriction. The annual loss due to mortality ranges from 8% to 10% for cattle, 12% to 14% for sheep and 11% to 13% for goats. It is around

56.9% for poultry. The direct and indirect losses from livestock disease have significant economic, food security and livelihood impacts on livestock keepers and the national economy (MOA, 2013). Cultivated crop area accounts for a relatively small share of the total area of Ethiopia because most land is not suited for cultivation. Cereals dominate Ethiopian crop production. As of 2011, cereals were grown on 73.4% of the total land area and cultivated by 11.2 million farmers (IFPRI, 2011).

The human health system structure has three tiers, consisting of primary health care (primary care hospitals, health centres and health posts), secondary health care (general hospitals) and tertiary health care (comprehensive–specialized and subspecialized hospitals). According to the 2019–2020 Ethiopian health and health-related indicators, there are 400 public hospitals, 52 private hospitals, 3800 health centres, 18 000 health posts, 6500 other private health facilities and 6000 medicine retail outlets (MOH, 2020a).

The Government delivers most animal health services. There are 743 public and 877 private veterinary clinics, 4760 veterinary health posts, 4 veterinary teaching hospitals and 1205 veterinary drug retail outlets.

The number of primary, secondary and tertiary education facilities has increased dramatically in the country, and the number of students enrolled was an estimated 30 million in 2019–2020. Ethiopia has 44 public universities. Private higher education enrolled at least 15% of all undergraduate students in 2015. In addition to public universities, there are 32 public teacher training colleges and 11 technical and vocational education and training institutes. And 14 universities provide training for veterinary and animal health professionals (MOE, 2020).



1.2 ANTIMICROBIAL RESISTANCE OVERVIEW

Antimicrobial resistance poses a grave global threat to human, animal and plant health and the environment. It causes an estimated 700 000 deaths every year. Failing to tackle antimicrobial resistance could, by 2050, cause an estimated 10 million deaths a year and cost up to \$100 trillion. The highest impact likely will be in Asia and Africa, which likely will account for an estimated 4.7 million and 4.2 million deaths, respectively (O'Neil, 2014). In Ethiopia currently, misuse of antimicrobials is common among human and animal health care providers, unskilled and animal husbandry practitioners and drug users (MOH, 2020a). Various studies reflect an alarming rate of antimicrobial resistance.

The Government of Ethiopia joined the global community in tackling the threat of antimicrobial resistance with a national strategic framework in 2011 (EFDA, 2011). It then followed with the first Strategy for the Prevention and Containment of Antimicrobial Resistance, in 2015 (EFDA, 2015). Ethiopia now embraces a concerted, collaborative and integrated One Health approach to manage the antimicrobial resistance threats appropriately and effectively across the human, animal and plant health, the food and feed production and the environment sectors. It works on better managing water, sanitation, hygiene and wastewater to prevent infections and contain pollution.

Situation analysis and assessment

The Government has undertaken various efforts to prevent and contain antimicrobial resistance. However, the previous human and animal health sector strategies as well as environmental sector strategies have not comprehensively addressed antimicrobial resistance prevention and containment.

Various studies show an alarming rate of antimicrobial resistance in Ethiopia. A systematic review of Salmonella spp. (Tadesse, 2014) and Shigella spp. (Hussen, Mulatu and Yohannes Kassa, 2019) found high resistance for the commonly used antibiotics. Similarly, high E. coli resistance was seen not only for the commonly used antibiotics (access group) but also for third-generation cephalosporins and fluoroquinolones (Sisay, Mengistu and Edessa, 2018; Tuem et al., 2018).

The emergence and prevalence of resistant strains in agricultural food products also seriously compromise the public health. According to a systematic review of studies published from 2013 to 2018, out of the 556 E. coli isolates from different food sources in Ethiopia, resistance to ampicillin, erythromycin and streptomycin have been reported, at 78.7%, 64.1% and 37.6%, respectively (NAHDIC, 2019). Similarly, among 205 Salmonella spp. isolated from food sources, resistance of 64.6% for Streptomycin, 45.1% for ampicillin and 39.1% for tetracycline were reported. Lower percentages of resistance were recorded for gentamycin, ceftriaxone and ciprofloxacin (NAHDIC, 2019, p. 8). Ethiopia has not yet taken action in avoiding or voluntarily phasing-out antimicrobial-growth promoters and non-therapeutic use of antimicrobials in animals, as promoted by research and evidence.

An alarming magnitude of multidrug-resistant infections has been found in a few recent systematic reviews and meta-analyses. According to the 2020 systematic review and meta-analysis, the pooled proportion of extended spectrum beta-lactamase-producing gram-negative bacteria was 50% (Tufa et al., 2020). In addition, the pooled vancomycin-resistant Enterococci estimate accounted for 14.8% (Melese, Genet and Andualem, 2020). Out of 238 gram-negative bacilli isolates, nearly 2% were carbapenem-resistant (Beyene et al., 2019).

The prevalence of multidrug-resistant tuberculosis among newly diagnosed patients has ranged from 2% to 2.7% (Girum et al., 2018; Eshetie et al., 2017; Kebede et al., 2014). Multidrug-resistant tuberculosis is mainly associated with history of previous treatment and to a lesser extent with contact history. Meta-analyses have reported a prevalence of 15% (Eshetie et al., 2017) and 21% (Girum et al., 2018) among previously treated patients.

The 2019 findings of the national antimicrobial resistance surveillance for the priority pathogens augment the evidence from previous reports for the different studies (EPHI, 2019). Although the

data were heterogenic, hospital-based and with less geographic representation, the findings cited here warn of the risks that antimicrobial resistance poses to public health.

Despite the World Health Organization's (WHO) recommendations, antimicrobials prescriptions are widespread in Ethiopia. The average percentage of prescriptions containing antibiotics is 57.6% (MOH, 2020a). Antimicrobial prescriptions are mainly driven by empiric decision (Gebretekle et al., 2020; Gutema et al., 2018). Antimicrobial prophylaxis is used in the majority of surgical procedures, including clean surgical procedures. It is found in wrong doses, duration and indication at levels above what is recommended (Alemkere, 2018).

The irrational and overuse of antimicrobials is driven by poor availability and compliance with standard treatment guidelines, the functionality of the Drug and Therapeutic Committee and Drug Information Services. (MOH, 2020b). Clients' adherence to the prescribed antimicrobials and self-medication practice have been found to be major problems (Sisay, Mengistu and Edessa, 2018; Ayalew et al., 2017; Hailu et al., 2014).

In general, improving evidence-based awareness is still an urgent agenda requiring surveillance on responsible antimicrobial use, residue and resistance trends in food and feed production and in the environment to prevent and contain antimicrobial resistance (O'Neil, 2016).

One Health perspective

In 2015, WHO developed the Global Action Plan on Antimicrobial Resistance, in collaboration with the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (OIE). It was then adopted by the World Health Assembly. The Global Action Plan highlights the One Health approach, which is a collaborative, multisector and transdisciplinary approach adopted as the global framework for streamlining collaboration among different sectors, in this case, to prevent and contain antimicrobial resistance (WHO, 2015).

Ethiopia is fully committed to the collaborative, multisector and transdisciplinary approach, which is supported by the national One Health platform that involves the active participation of multiple stakeholders. Indeed, several policy documents recommend multi-stakeholder and multidisciplinary approaches to better address complex public health issues. The Government endorsed the Public Health Policy of Ethiopia (1993), the Animal Diseases Prevention and Control Proclamation (No. 267/2002) and the National One Health Strategic Plan (2018–2022). All these policies support the adoption of the One Health approach.

Although Ethiopia initiated antimicrobial resistance prevention and containment implementation early and has made much progress, the Government recognizes that the country lags behind the antimicrobial resistance threats and risks, which are still high due to inadequate multisector harmonizing, insufficient and low-quality data on antimicrobial use and resistance, lack of sustainable financing, suboptimal practices, an inadequate number of trained professionals and insufficient laboratories and supplies.

Country response

In Ethiopia, antimicrobial resistance advocacy and containment efforts began back in 2006. The first antimicrobial resistance stakeholders meeting was conducted in March 2006, followed by the establishment of the National Antimicrobial Resistance Advisory Committee under leadership of the Drug Administration and Control Authority of Ethiopia (now the Ethiopian Food and Drug Authority). The major initiative was capacity-building activities targeting the Drug and Therapeutic Committee as an entry point to support the antimicrobial resistance containment effort.

A baseline survey on antimicrobial use, resistance and containment was conducted in 2008 and showed a high level of antimicrobial resistance (DACA, 2009). Following identification of gaps and targets, the first strategic framework for antimicrobial resistance prevention and containment was developed in 2011 (EFDA, 2011). The second strategy was released in October 2015, covering

2015-2020 (EFDA, 2015).

In April 2017, Ethiopia developed and approved the National Antimicrobial Resistance Surveillance Plan. It aimed at establishing a national surveillance network capable of detecting priority antimicrobial resistance pathogens, analysing and reporting data, characterizing resistance and generating evidence to inform the implementation of targeted prevention and control programmes. Three rounds of annual antimicrobial resistance surveillance reporting on priority pathogens from the sentinel sites have been released so far (2018–2020). In addition, the integrated National Antimicrobial Resistance and Residue Surveillance Plan (2019–2023) for the animal health, plant, food safety and environment sectors. Led by the National Animal Health Diagnosis and Investigation Center, it offers great hope. Another baseline survey was conducted in 2018 on the awareness of veterinary drug retail outlets on the trends of antimicrobial resistance and its containment strategies. The survey revealed that pre-service and in-service training on antimicrobial use, resistance and containment are not well addressed in terms of dispensers, over-the-counter dispensing of antimicrobials when directly asked by animal owners and the traditional way of dispensing antimicrobials without evidence-based tools and aids (such as sensitivity test, veterinary standard treatment guidelines, the veterinary medicines formulary, prescription paper, etc.) (Zeru et al., 2019).

Different antimicrobial resistance prevention and containment activities have been implemented. Including but not limited to:

- Conducting advocacy and communication efforts through different forums and media capacity-enhancement activities in the human and animal health sectors;
- Cascading the national antimicrobial resistance action plan to regions and establishment of regional antimicrobial resistance advisory committees;
- Implementing the antimicrobial stewardship programme in selected public and private hospitals;
- Revising the infection prevention and control guidelines, development of an infection prevention and control policy and implementing infection prevention and control practices;
- Revising the national veterinary drug list with restrictions of highest-priority critically important antibiotics for animal use;
- Developing and implementing the rational medicine use directive, which restricts-over-the counter use of antimicrobials;
- Revitalizing the antimicrobial resistance governance structure;
- Revising standard treatment guidelines (human and animal health) and the essential medicines list, incorporating the who access, watch and reserve (aware) categorization of antibiotics;
- Reporting annually the antimicrobial resistance surveillance findings to the who global antimicrobial surveillance and use system;
- Providing national antimicrobial consumption surveillance training in two rounds; and
- Commemorating national antimicrobial days.

Governance structure

Since 2019, the governance framework of antimicrobial resistance prevention and containment transitioned from the Ethiopian Food and Drug Authority (the former Drug Administration and Control Authority) to the Ministry of Health. The current antimicrobial resistance governance mechanism comprises a high-level National Inter-ministerial Committee, the National Antimicrobial Resistance Advisory Committee, a national antimicrobial resistance focal point (AMR secretariat) and six multisector technical working groups (on awareness and education; research and surveillance; infection prevention and control and hygiene; antimicrobial stewardship; regulations and pharmacovigilance;

and partnership and resource mobilization) to address the strategic objectives of the national action plan (see the Annex for the terms of reference for the membership, duties and responsibilities of each governance body). National-level governance is responsible for formulating policies and regulations and providing technical guidance and assistance to regional-level antimicrobial resistance coordinating platforms. Regional antimicrobial resistance governance oversees and assists implementation of the antimicrobial resistance prevention and containment strategy at all levels.




Figure 1 Antimicrobial resistance governance framework

SWOT ANALYSIS OF THE ANTIMICROBIAL RESISTANCE SITUATION IN ETHIOPIA

Table 1. Analysis of the strengths, weaknesses, opportunities and threats regarding antimicrobial resistance prevention and control

| Str | engths | Weaknesses |
|-----|---|---|
| | Availability of legal provisions in human, agriculture and environment sectors | Weak collaboration system among major antimi- crobial resistance stakeholders at all levels |
| • | Existence of regulatory bodies for medicine and medical devices and professional conduct in the human and animal health and environment sectors | Inadequate antimicrobial resistance surveillance capacity and utilization of evidence generated for decision-making |
| | Existence of antimicrobial resistance governance structure at national and regional levels (Advisory Committees and AMR secretariat) and a One Health Steering Committee | Inadequate sustainable financial, human and material resources |
| • | Existence of guidelines (Antimicrobial Stewardship I, standard treatment guidelines, infection prevention and control) and directives (Rational Medicine Use II) in the human and animal health sectors | Inadequate awareness and commitment on anti- microbial resistance among policymakers and the general population. |
| • | Efforts undertaken to improve awareness on antimicrobial resistance | Inadequate ownership and cascading of a national strategy for antimicrobial resistance by key stake- holders at national, regional and city administra- tion and institution levels |
| | Launching of the Antimicrobial Stewardship Programme in selected public and private hospitals | Irrational antimicrobial prescribing, dispensing and use |
| | Efforts underway to integrate infection prevention and control practices with antimicrobial stewardship, such as integrated training | Poor laboratory infrastructure and inadequate microbiology supplies |
| | Established antimicrobial resistance surveillance system in the human and animal health sectors | Lack of standards in existing food legislation on antibiotic residues |
| | Presence of research and public health laboratory networks at national, regional and academic public health research laboratories | Inadequate regulation of antimicrobials, including market surveillance, inspection of antimicrobial use and enforcement and safe disposal of waste |
| | Existence of accredited reference national bacteriology laboratory in the human and animal health sectors | Inadequate institutionalized implementation of antimicrobial stewardship |
| | | Inadequate pre- and in-service training on proper use of antimicrobials and laboratory diagnostic testing capacity |
| | | Poor community and health facility infection prevention and control programme |
| | | Poor animal husbandry practice and bio-risk management |
| | | Absence of a reporting, monitoring and evaluation system |
| | | Lack of interoperability database and reporting system among human, animal and environment surveillance |

| Opportunities | Threats |
|--|--|
| Existence of health and agriculture extension pro- grammes to reach communities and primary health care settings to strengthen awareness, appropriate prescribing and prevention efforts | Borderless transmission of resistant pathogens |
| Existence of ample international experience and research findings in the field | Emergence and re-emergence of infectious diseases |
| Commitment of international organization in com- bating antimicrobial resistance including WHO, FAO, OIE, Africa Centres for Disease Prevention and Control (CDC), United States Agency for International Development (USAID) and other partners | Inadequate number of new antimicrobials in the research and development pipeline |
| Availability of advanced technology | Competition of scarce resources and inflation |
| Availability of various print and electronic media | Circulation of substandard and falsified medical products due to porous borders |
| Availability of higher education institutions | Pressure from pharmaceutical companies |
| Improved primary and secondary education coverage | |

STAKEHOLDER ANALYSIS

The Government of Ethiopia has identified all relevant antimicrobial resistance stakeholders and presumes their engagement is essential for combating antimicrobial resistance. The majority of stakeholders are already members of the National Antimicrobial Resistance Advisory Committee. However, based on national and regional assessment findings, there is little coordinated engagement and governance among these stakeholders (MOH, 2020a; 2020b; 2019).

Table 2 Stakeholder analysis for antimicrobial resistance prevention and containment

| Stakeholders | Level of involve-ment | Desired behaviours | Their needs | Anticipat- ed chal- lenges | Institutional response |
|---|-----------------------|---|--|---|---|
| -Ministry of Health (MOH) and its agencies (EPSA, EPHI), AHRI) and regional counterparts -Ministry of Agriculture (MOA) and its agencies (NAHDIC) and regional counterparts -Environment, Forest and Climate Change Commission (EFCCC) and its agencies (Ethiopian Environment and Forest Research Institute (EEFRI), Ethiopian Biodiversity Institute (EBI)) and regional counterparts | High | Advocacy and ownership of AMR Leadership and coordination Develop and update polices and legal frameworks Plan and allocate resources Information exchange Collaboration Efficient utilization of resources Transparency of operations Accountability | Technical and financial support Appropriate data for decision-making Information exchange Collaboration | Inadequate collaboration information sharing leadership support | Update continuously information and lobbying Review gaps and address swiftly Strengthen collaboration Establish joint monitoring and evaluation |
| Regulatory bodies -EFDA, -EFCCC - VDFACA and regional counter- parts | High | Advocacy and ownership of antimicrobial resistance Plan and allocate resources Effective enforcement Transparency and accountability | Technical and financial support Appropriate data for decision-making Information exchange Collaboration | Inadequate enforcement information sharing leadership support Duplication of efforts | Establish joint monitoring and evaluation Strengthen collaboration Design mechanisms that avoid duplication of efforts |

| Stakeholders | Level of involve-ment | Desired behaviours | Their needs | Anticipat- ed chal- lenges | Institutional response |
|--|-----------------------|--|--|---|---|
| Civil society | Medium | Promote ethical practices Lobby government to ensure availability and rational use of antimicrobials and personal protective equipment Antimicrobial resistance advocacy | Recognition Technical and financial support Supportive policies\y | Lack of buy-in Expose un- acceptable practices | Identify the resist- ance areas and respond based on the findings Engage and partic- ipate in planning, monitoring and evaluation |
| Professional associations (relative to human, animal and plant health and the environment) | High | Antimicrobial resistance advocacy Promote infection prevention and control and antimicrobial stewardship Provide continuing professional development on antimicrobial resistance, use, consumption and stewardship, infection prevention and control, etc. Develop standards and protocols Research and development Antimicrobial resistance curriculum review | Technical and financial support Exchange of information | Weak collaboration Loss of trust | Engage in planning, implementation, monitoring and evaluations |
| Communities and patients, animal owners, clients | High | Compliance and adherence to medications Avoid self-medication Participation, engagement and ownership Avoid non-therapeutic use of antimicrobials | Safe, quality and effective medicines Safe water, sanitation and hygiene facilities Up-to-date and reliable information Engagement and empowerment | Non-compliance Dissatisfaction Opting for poor quality and unsafe alternatives Distrust | Ensure sustained access to good-quality and safe medical products Provide up-to-date, reliable and proper information Engagement and participation in planning, monitoring and evaluation |

| Stakeholders | Level of involve-ment | Desired behaviours | Their needs | Anticipat- ed chal- lenges | Institutional response |
|---|-----------------------|---|---|---|--|
| Public and private health facilities and diagnostic centres (animal and human) and pharmaceutical establishments | High | Ethical and rational use of medicines Institutionalize and integrate infection prevention and control and/or antimicrobial stewardship Participation in public awareness-raising efforts Empower their professionals on antimicrobial resistance | Up-to-date information, standard treatment guidelines and formularies Technical and financial support Supportive policy environment | Unethical practices Refusal to follow standards Inappropriate use of resources | Measures on illegal practices Provision of information Technical support Engagement and participation in planning, monitoring and evaluation |
| Ministry of Science and Higher Edu- cation (MOSHE), Ministry of Educa- tion (MOE), Ministry of Information and Technology, aca- demia and research institutions | High | Inclusion of antimicrobial resistance in curriculum and courses Technical assistance Evidence-generation and advocacy on antimicrobial resistance Serve as centre of excellence Innovations | Technical and financial support and collaboration Engagement and participation Information exchange | Poor attention to antimicrobial resistance Dissatisfaction Poor infrastructure or budgeting | Transparency and collaboration Use of evidence and reports generated Up-to-date information Engagement and participation in planning, monitoring and evaluation |
| Media | High | Awareness-raising on antimicrobial resistance, sanitation, hygiene and infection prevention and control measures Broadcast achievements and best practices Provision of right information to the public on antimicrobial resistance Lobby the Government to combat antimicrobial resistance | Resources for generating up-to-date and reliable information Transparency and participation Technical support Supportive policy Provision of reliable information | Less attention Dissemination of unreliable information Broken trust | Provide up-to-date and reliable information Strengthen collaboration and integrated works Create transparent and participatory platforms for the media |

| Stakeholders | Level of involve-ment | Desired behaviours | Their needs | Anticipat- ed chal- lenges | Institutional response |
|--|-----------------------|--|--|--|---|
| Tripartite organizations (World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (OIE) | High | Technical and financial support Advocacy, harmonization and alignment of antimicrobial resistance, infection prevention and control, antimicrobial stewardship, food and feed safety and biosecurity agendas with the global strategy Development and issuance of manuals, guidelines, policy documents Monitoring and evaluation | Efficient utilization of resources Timely reporting and feedback | Reduced technical and financial support Low evaluation of performance reports | Transparency Alignment and harmonization Engagement and collaboration |
| International organizations and development partners (CDC, United States Agency for International Development (USAID), UNICEF, United Nations Environment Programme, World Bank, European Union, etc.) | High | Technical and/or financial support Engagement on advocacy and promotion of antimicrobial resistance prevention and containment activities, such as infection prevention and control practice, antimicrobial stewardship implementation, research, surveillance, awareness and education | Harmonized and transparent system Participation in planning, monitoring and evaluations Collaboration and engagement | Denial of support or cooperation | Transparency Efficient resource use Collaboration and engagement Provision of up-to- date information |

| Stakeholders | Level of involve-ment | Desired behaviours | Their needs | Anticipat- ed chal- lenges | Institutional response |
|---|-----------------------|--|--|--|---|
| Health professionals (human and animal) | High | Compliance with good prescribing and good dispensing practices Compliance with standard treatment guidelines Refrain from dispensing antimicrobials over the counter Ensuring quality-assured laboratory results Compliance with infection prevention and control practice recommendations | Availability of safe, effective and quality products Pre-service and in-service capacity-building Efficient and fair service and system from the regulatory enforcement Updated information and legal framework | Uncooperativeness Distrust Poor compliance with standards and legal frameworks Poor communication among professionals | Efficient and fare quality assurance system Updating laws and information |
| Ministry of Finance | High | Recognition of antimicrobial resistance as a social, economic and health threat requiring a multisector approach Understand the benefit of investing in antimicrobial resistance and value for money Allocate required resources for antimicrobial resistance issues | Justification among the competing government priorities and economic benefit Efficient and effective utilization of budget Timely liquidation and reporting | Hesitation or refusal of allocating and approving budget Inadequate information on economic impact of antimicrobial resistance Confidence on the deliverables Budget shortage and competing priorities | Utilize budget properly Demonstrate the results and benefits of investing in antimicrobial resistance prevention Mobilize resource Develop convincing justifications in case of deviations in the implementation |

| Stakeholders | Level of involve-ment | Desired behaviours | Their needs | Anticipat- ed chal- lenges | Institutional response |
|---|-----------------------|--|--|--|--|
| Parliamentarians, community leaders and opinion leaders | Medium | Advocacy of rational medicine use laws and practices Cooperation Monitoring and follow-up Approval and monitoring of enforcement of the legal frameworks | Availability of safe and good-quality medicines Proper drafting legal frameworks Information exchange Timely performance reporting | Unacceptance Deny cooperation Influence on budget allocation | Embrace the approach and engagement Review gaps and address them Embrace capacity-building mechanisms Execute authority and responsibility properly Provide proper information |

CRITICAL ISSUES AND CORE ENABLERS RELATED TO ANTIMICROBIAL RESISTANCE

Table 3 Critical issues and core enablers related to antimicrobial

resistance

| Critical issues | Core enablers |
|---|---|
| Inadequate multisector govern- ance, collaboration, coordination | Strengthen the national and regional Antimicrobial Resistance Advisory Committees |
| and commitment at all levelsResource constraints | Establish and strengthen AMR secretariat, team and focal persons |
| Inadequate needs-based research, diagnostic facilities and | Strengthen the multisector antimicrobial resistance technical working groups |
| antimicrobial resistance, use and consumption surveillance for decision-making | Mobilize aggressive and sustainable resources |
| - | Strengthen partnership and networking |
| Inadequate awareness on threats of antimicrobial resistance | Strengthen communication and coordination forums |
| among policymakers, profes- sionals and the general popula- tion | Nominate goodwill ambassadors on antimicrobial resistance |
| Poor infection prevention and control practices and lack of in- tegration of infection prevention and control with the Antimicrobi- | Promote antimicrobial resistance knowledge and behaviour change among decision-makers, professionals and the general public through printed and electronic media |
| Irrational use of antimicrobials and circulation of substandard | Strengthen sentinel surveillance sites and research to generate evidence to improve health care outcomes and decision-making |
| and falsified medical products | Access and ensure applicability of up-to-date treatment guidelines |
| | Institutionalize and integrate Antimicrobial Steward- ship Programme and infection prevention and control programme into the human and animal health sectors |
| | Improve regulatory enforcement of antimicrobial use, prescribing, dispensing and self-medication as well as prevention, detection and response to substandard and falsified medical products, including participation in WHO global surveillance and monitoring system and member State mechanisms regarding substand- ard and falsified medical products |
| | Establish and strengthen a monitoring and evaluation system |
| | Strengthen innovation and adoption of technologies |


2. RATIONALE FOR REVISIONS IN THE THIRD STRATEGIC PLAN

The second edition of the National Antimicrobial Resistance Prevention and Containment Strategy 2015–2020 was well aligned with the WHO Global Action Plan on Antimicrobial Resistance. But the strategy needed revision, primarily for the following reasons.

- It was not comprehensive enough to address the animal, fisheries, plant, food production and environment sectors.
- The roles and responsibilities of key stakeholders, including private sector engagement, were not clearly articulated.
- It lacked a robust operational plan; a clear line of reporting, monitoring and evaluation and accountability, costing and required resources.
- The strategy was overambitious, which had been difficult to implement in the specified period.
- It needed to integrate recent global and national antimicrobial resistance-related updates.

Completion of the implementation period became the right time to revise the national strategic plan to address these gaps and align with the country's Growth and Transformation Plan for health, agriculture and the environment.

3. STRATEGIC PLAN



3. STRATEGIC PLAN

In line with the World Health Organization's Global Action Plan on Antimicrobial Resistance and country's Growth and Transformation Plan for the health, agriculture and environment sectors, the third national strategic plan on prevention and containment of antimicrobial resistance is designed to ensure continuity of the successful approaches already practised for the prevention, control and treatment of infectious diseases in humans, animals and plants through multisector collaboration. Hence, the third AMR prevention and containment strategic plan consists of 5 strategic objectives with 22 initiatives, 66 interventions and 180 operational plans with costing and a monitoring and evaluation framework.

- Improve awareness and understanding of antimicrobial resistance through effective behaviour change communication, education and training.
- Strengthen the knowledge and evidence on antimicrobial use and resistance through surveillance and research.
- Enhance infection prevention and control through effective environmental health, infection prevention and bio-risk measures in human, animal and plant health.
- 4. Optimize the use of antimicrobials in human, animal and plant health care.
- Strengthen and establish partnerships, alliances, governance and resource mobilization at all levels.




Figure 2. Strategic Objectives of National AMR Strategic Plan

3.1 OBJECTIVE ONE:

IMPROVE AWARENESS AND UNDERSTANDING OF ANTI-MICROBIAL RESISTANCE THROUGH EFFECTIVE BEHAVIOUR CHANGE COMMUNICATION, EDUCATION AND TRAINING

Description

Antimicrobial resistance prevention and containment shall be seen as everyone's responsibility. All human, animal and plant health professionals, environment professionals, public and private institutions, policymakers and communities shall understand the extent and the challenges posed by antimicrobial resistance. Some institutions had raised awareness and expanded knowledge on antimicrobial resistance. However, awareness, understanding of the problem and the attention given to antimicrobial resistance prevention and containment by communities, professionals and policymakers remain inadequate

This strategic objective is designed to encourage a whole-of-society approach in tackling the issue of antimicrobial resistance and ensure that everyone is aware of the problem and challenges. It also seeks to ensure that individuals, communities and institutions understand their role in addressing antimicrobial resistance through effective behaviour change communication, education and training. The objective aims to improve behaviour change on antimicrobial use and resistance among the targeted groups.

This objective involves 4 initiatives, 8 interventions and 18 activities, as explained in the operational plan.




Figure 3. Strategic Initiatives for Awarness and Education Strategic Objective

Table 4: Initiatives and interventions for objective one

Objective 1: Improve awareness and understanding of antimicrobial resistance through effective behaviour change communication, education and training

| effective behaviour change communication, education and training | | | | |
|--|----|---|--|--|
| Strategic initiatives | | Strategic intervention | | |
| Improve awareness, understanding and | | Design and promote sustainable whole-of-society engagement through effective communication platforms | | |
| empowerment of clients and communities | 2. | Incorporate personal, public and food hygiene, sanitation, nutrition, good farming and environment health-control practices related to antimicrobial use and resistance into school curricula and extracurricular activities | | |
| | 3. | Raise awareness of clients and the public on rational use of antimicrobials and adherence to treatment and professional advice through health education and training | | |
| | 4. | Improve awareness of the risk of leftover antimicrobials, pesticides, insecticides and heavy metals in the environment | | |
| Education and training on antimicrobial resistance for human, animal, plant and environmental professionals in public and private institutions | | Incorporate antimicrobial resistance in course content of technical and vocational education and training, undergraduate and post-graduate curricula | | |
| | | Develop and implement regular and needs-based pre-graduation and in-service training and continuous professional development programmes on antimicrobial use, resistance and stewardship and infection prevention and control, including for health and agriculture extension workers | | |
| Empower the media (public and private) and engage civil society organizations on antimi- crobial resistance | | Capacitate media and civil society on antimicrobial resistance to ensure their engagement in educating the public | | |
| Advocacy and commu- nication with policymak- ers and decision-makers | | Advocate antimicrobial resistance as a national and global priority with pertinent policymakers and decision-makers to mainstream prevention and containment | | |

3.2 OBJECTIVE TWO:

STRENGTHEN THE KNOWLEDGE AND EVIDENCE ON ANTI-MICROBIAL USE AND RESISTANCE THROUGH SURVEILLANCE AND RESEARCH

Description

Surveillance and research on antimicrobial use, consumption and resistance, antimicrobial residues and market surveillance are essential in preventing and guiding the management of infectious diseases. It is necessary for updating infection-control policies and practices. It is also critical to provide early warning of emerging and re-emerging human, animal and plant infectious diseases, to monitor changing patterns of resistance and to target and evaluate antimicrobial resistance prevention and containment measures.

Establishing and strengthening laboratory diagnostic testing through standardizing methods and procedures for surveillance and research on antimicrobial use, consumption and resistance can ensure and generate quality data to influence health care outcomes and policy and programme implementation. An effective network that generates and collates data on surveillance of antimicrobial use, consumption and resistance across the human, animal and environmental interface will be established. This objective focuses on strengthening and standardizing surveillance and research through the One Health approach. It involves 4 initiatives, 14 interventions and 47 activities, as explained in the operational plan. Hence, information and evidence will be generated for decision-making.



Table 5: Initiatives and interventions for objective two

Objective two: Strengthen the knowledge and evidence on antimicrobial use and resistance through surveillance and research

| Strategic initiatives | Strategic interventions |
|---|--|
| Establish and strengthen surveillance of antimicrobial resistance priority pathogens in human and animal health, feed and food safety, plants and the environment. | Establish and strengthen antimicrobial resistance surveillance systems to detect and report antimicrobial resistance and disseminate information to facilitate evidence-based decision-making at all levels in all sectors Establish multi-institutional networks to collate and channel surveillance reports and case studies on antimicrobial resistance and informed policymaking and decision-making Establish real-time patient and population-based antimicrobial resistance surveillance system Strengthen and maintain a national bio-repository on antimicrobial resistance priority organisms, strains and genes Establish alert system on emerging and re-emerging antimicrobial resistance issues that do have public and animal health emergency importance |
| Build up the capacity for a quality management system of laboratories for human, animal and plant health and for feed and food safety and environment testing at the national, regional and facility levels | Standardize microbiology laboratory methodologies and techniques including advanced detection methods Establish and strengthen laboratory facilities and equipment maintenance and calibration centres Build up the capacity of human resources for specimen management, for conducting culture, identification and antimicrobial sensitivity tests and for reporting to the human, animal, environment, feed and food sectors using phenotypic and molecular methods Strengthen the laboratory information management system |
| Basic and operational research | Conduct basic and operational research on antimicrobial use, consumption and resistance. Research diagnostic and treatment alternatives for infections that can be treated with antimicrobials Introduce innovative technologies and research on rapid diagnostic tests and methods for infections and antimicrobial resistance Develop an AMR index to communicate gaps in antimicrobial effectiveness and help aggregate data on resistance to assess trends over time and across locations |
| Establish and strengthen surveillance and research of antimicrobial contaminants and residues and the drivers of antimicrobial resistance in the environment, plant, food and feed sectors | Establish and strengthen surveillance and research of anti- microbial residues, effluent and waste in the environment, plant, food and feed sectors |

3.3 OBJECTIVE THREE:

ENHANCE INFECTION PREVENTION AND CONTROL THROUGH EFFECTIVE ENVIRONMENTAL HEALTH, INFECTION PREVEN-TION AND BIO-RISK MANAGEMENT IN HUMAN, ANIMAL AND PLANT HEALTH CARE

Description

Infection prevention and control along with water, sanitation and hygiene measures in human and animal health facilities and in communities reduces the risk of transmission of infections. It also minimizes the need for and use of antimicrobials and prevents the subsequent emergence of resistant strains. Infection prevention and control measures contain the spread of resistant microbes once resistance has emerged. These measures include personnel hygiene and environmental health, specifically water, sanitation and hygiene in communities and health care facilities; promoting vaccinations; improving safety in risky areas of health facilities for humans and animals; safe wastewater and waste management practices; isolation of patients infected by highly contagious microorganisms; good animal husbandry practices; and biosafety and bio-risk management.

This strategic objective is designed to reduce the occurrence of infections and contain the spread of the resistant strains in communities and in veterinary and human health care settings through implementation of a range of recommendations and minimum requirements related to the existence of functional and effective infection prevention and control programmes to reduce the incidence of infection at the national and facility levels.

This strategic objective involves 5 initiatives, 13 interventions and 37 activities, as explained in the operational plan.




Figure 4. Strategic Initiatives for IPC and Hygiene Strategic Objective.

Table 6: Initiatives and strategic interventions for objective three

Objective three: Enhance infection prevention and control through effective environmental health, infection prevention and bio-risk measures in human, animal and plant health care

| health, infection prevention | and | d bio-risk measures in human, animal and plant health care |
|--|-----|---|
| Strategic initiatives | Stı | ategic interventions |
| Strengthen and promote an infection prevention and control programme | 1. | Coordinate multisector collaboration to limit the emergence, re-emergence and spread of antimicrobial resistance and multiple drug-resistant organisms in humans, animals, plants and the environment |
| for human, animal and plant health care and for the environment | 2. | Set and enforce standards on infection prevention and control as per the One Health approach |
| the environment | 3. | Develop protocols and guidelines for infection outbreak detection and case management due to antimicrobial resistance and multiple drug-resistant strains |
| Strengthen infection prevention and control prac- | 1. | Ensure implementation of safe infection prevention and control practices in human and veterinary health facilities |
| tices in public and veteri- nary health facilities | 2. | Prevent and monitor health care-associated infections in human and veterinary health facilities |
| | 3. | Strengthen prevention of zoonotic diseases |
| Strengthen good animal | 1. | Promote bio-risk management and good husbandry practices |
| husbandry practices | 2. | Integrate antimicrobial resistance prevention and containment activities with veterinary outreach services and vaccination access |
| Promote personal hygiene | 1. | Promote personal and environmental hygiene and sanitation |
| and strengthened water, sanitation and hygiene | 2. | Promote, implement and enforce proper waste management at the community level |
| services at the community level | 3. | Encourage and promote safe water supply and sanitation services for humans and animals |
| Strengthen the information system for infection | 1. | Develop a multisector infection prevention and control information communication management system (database) |
| prevention and control management | 2. | Generate and disseminate evidence-based information to improve infection prevention and control practices and decision-making processes |

3.4 OBJECTIVE FOUR:

OPTIMIZE THE USE OF ANTIMICROBIALS IN HUMAN, ANIMAL AND PLANT HEALTH CARE

Description

Countries, regions or human and veterinary health care facilities with high antimicrobial use and misuse are associated with high incidence of resistance. Inadequate capacity to diagnose and manage infectious diseases, poor prescribing and dispensing practices, poor adherence to treatments, substandard and falsified medicines and outdated and biased medicine information, poor access to antimicrobials and wrong duration of therapy are all important contributors to antimicrobial resistance.

Evidence-based policies, protocols and regulations that encourage more appropriate and rational use of antimicrobials are key interventions for the containment of antimicrobial resistance. This strategy involves strengthening and integrating antimicrobial stewardship into health care facilities. It also promotes using data on antimicrobial use, consumption and resistance to trigger changes in the behaviour of human and veterinary health care professionals, clients and other actors in the human and animal sectors.

This objective involves 5 initiatives, 24 interventions and 50 activities, as explained in the operational plan.



Figure 5. Core Elements of Anti-Microbial Stewardship

Table 7: Initiatives and strategic interventions for objective four

Objective four: Optimize the use of antimicrobials in human, animal and plant health care

| | use of antimicrobials in human, animal and plant health care |
|--|--|
| Strategic initiatives | Strategic interventions |
| Improve access to quality antimicrobials and labora- | 1. Ensure effective supply chain management of quality essential antimicrobials and laboratory supplies |
| tory supplies in the human and animal health sectors | 2. Promote local production of quality antimicrobials and laboratory supplies |
| Ensure optimal prescribing, dispensing and use of antimicrobials in human health | Integrate antimicrobial stewardship into the Ethiopian Hospitals Services Transformation Guideline and the Ethiopian Health Centre Reform Implementation Guideline |
| care | 2. Ensure implementation of antimicrobial stewardship in health care facilities |
| | 3. Ensure the availability of and monitor compliance to updated and evidence-based guidelines, policies, manuals and formularies for the prescribing and dispensing practice |
| | 4. Strengthen antimicrobial use and consumption surveillance data for action to improve health care outcomes at health facilities and at the national level |
| | 5. Improve communication and team spirit among health care providers |
| Ensure optimal prescribing, | 1. Develop guidelines relevant to the prudent use of antimicrobials |
| dispensing and use of anti- microbials in animal health | 2. Develop and promote implementation of antimicrobial stewardship in veterinary services |
| | 3. Strengthen the diagnostic capacity of veterinary health services to promote the rational antimicrobial use and consumption |
| | 4. Strengthen the antimicrobial use and consumption surveying for veterinary health services |
| | 5. Strengthen professional and animal owner communication to optimize antimicrobial use and consumption |
| Strengthen diagnostic | 1. Establish, capacitate and standardize diagnostic laboratories |
| stewardship at health care facility level | 2. Ensure generation and utilization of antibiogram data at the health care facility level |
| | 3. Ensure prescribing practices of antimicrobials are based on laboratory diagnostic results |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Objective four: Optimize the use of antimicrobials in human, animal and plant health care

| Objective four. Optimize the | นรเ | e of antimicrobials in numan, animal and plant health care |
|--|-----|--|
| Strategic initiatives | St | rategic interventions |
| Strengthen the regulatory system in human, animal, | 1. | Review, develop and enforce legislation on the prudent use of antimicrobials and laboratory supplies |
| food and feed production and the environment sec- | 2. | Strengthen pre- and post-market surveillance and control of antimicrobials as well as laboratory and infection prevention and control supplies |
| tors | 3. | Capacitate regulatory bodies to ensure the availability and use of quality antimicrobial as well as laboratory and infection prevention and control supplies |
| | 4. | Regulate food preparation and dispensary centres to enhance food hygiene and safety |
| | 5. | Ensure proper disposal of unfit-for-use antimicrobials, laboratory supplies and residues |
| | 6. | Establish standards for waste discharge and treatment from manufacturing, food processing plants and human and animal health care settings |
| | 7. | Establish predicted no-effect environmental concentration values for |

resistance selection

3.5 OBJECTIVE FIVE:

STRENGTHEN AND ESTABLISH PARTNERSHIPS, ALLI-ANCES, GOVERNANCE AND RESOURCE MOBILIZATION AT ALL LEVELS

Description

Antimicrobial resistance is a global and national threat that requires concerted and coordinated national and international efforts to bring together various stakeholders. This will influence opinion, obtain support, mobilize action, harness the expertise and resources available in different sectors and improve governance.

All sectors must collaborate on innovations, resource mobilization and allocation, strengthen stewardship practices and infection prevention and control, address the threats of antimicrobial resistance, and move the issue of antimicrobial resistance to the political level.

This objective is designed to strengthen and establish partnerships, alliances, governance and resource mobilization efforts for the effective implementation of the national strategic plan at all levels.

The objective involves 3 initiatives, 6 interventions and 15 activities, as explained in the operational plan.




Table 8: Initiatives and strategic interventions for objective five

Objective five: Strengthen and establish partnerships, alliances, governance and resource mobilizations at all levels

| Strategic initiatives | Strategic interventions |
|---|---|
| Strengthen and establish governance, partnerships | Strengthen governance structures and collaboration of national and regional antimicrobial resistance stakeholders |
| and alliances | Strengthen collaboration with multilateral and bilateral organizations engaging in antimicrobial resistance prevention and containment |
| | 3. Promote public-private partnerships on antimicrobial resistance prevention and containment |
| Strengthen leadership | Ensure leadership, ownership and commitment for the sustainable implementation of the antimicrobial resistance strategic plan across sectors |
| Resource mobilization | 1. Ensure the availability of sustainable resources |
| | 2. Ensure resource mobilization to encourage innovations in the development of new antimicrobials, vaccines, diagnostics, novel therapies and/or alternatives |

4. OPERATIONAL PLAN

The national antimicrobial resistance prevention and containment strategic plan details an operational plan that describes activities to be implemented in line with the five strategic objectives. Priority area, interventions, detailed activity, indicator, time frame, frequency, lead implementer, collaborator and cost or budget have been identified.





4.1 Objective one:

IMPROVE AWARENESS AND UNDERSTANDING OF ANTIMICROBIAL RESISTANCE THROUGH EFFECTIVE BEHAVIOUR CHANGE COMMUNICATION, EDUCATION AND TRAINING

Table 9: Detailed operational plan for objective one

| Initiative 1.1: In | Initiative 1.1: Improve awareness, understanding and empowerme | empowerment of clients and communities | ities | | | | |
|---|--|--|--------------------------|--|---|---|------------------------------|
| Strategic interventions | Activities | Indicator | Time of imple-menta-tion | Fre- quency (with- in 5 years) | Lead imple- menter | Collabora- tors | Indicative ative budg (US\$) |
| Design and promote sustainable whole-of-so- | Develop comprehensive evidence-based national communication strategies for antimicrobial resistance in humans, animals, plants and the environment | Communication strategy developed | 2021– 2022 | <u>-</u> - | MOH, MOA, EFCCC and their regional counterparts | Professional associations, academia, media | 9450,0 |
| ciety engage- ment through effective enforcement of the One | Develop and disseminate information and education communication and behaviour change communication (printed and audio visual) materials targeting diverse beneficiaries, including people living with a disability | Number of information and education communication and behaviour change communication materials developed | 2021– 2025 | 10 | MOH, MOA, EFCCC and their regional counterparts | Media, civil society | 80 |
| Health approach and communication platforms | Conduct antimicrobial resistance awareness campaigns regularly (such as World Antimicrobial Awareness Week, AMR Day and other events) and collaborate with other campaigns that are linked to antimicrobial resistance to align and mainstream antimicrobial resistance messages (handwashing day, Ethiopian great run, culture day, children's day, etc.) | Number of campaigns conducted | 2021– 2025 | 01 | MOH, MOA, EFCCC and their re- gional counter- parts | Civil society, academia, media, part- ners | 125 |

00

| | 112 500,00 | 318 055,56 | 390 |
|------|--|---|--|
| | Academia, professional associations, partners | Opinion leaders, media, civil society | MOH, EFCCC, EFDA, VD- FACA and their regional counterparts |
| | MOH, MOA, EFCCC and their regional counterparts | MOH, MOA, EFCCC and their regional counterparts | MOA and its regional coun- terparts |
| | m | Ŋ | 25 |
| | 2021, 2023 and 2025 | 2021– 2025 | 2025 2025 |
| | Number of survey reports | Number of community platforms utilized | Number of training sessions |
| | Conduct survey (health professionals and community) to assess knowledge, attitudes and behavioural practice about antimicrobials use and antimicrobial resistance in human health, agriculture and the environment | Use multimodal strategies for mass community popularization on antimicrobial resistance using existing community platforms adapted to specific stakeholder groups and tailored to cultural contexts | Provide training for food, animal owners, handlers and processors about safe food production and alternatives to antimicrobials in public and private institutions |
| Cont | | | |

| 32 400.00 | 45 600.00 | 29 000.00 | 105 000.00 |
|--|---|--|---|
| MOE and their regional 4 counterparts | MOH, MOA, EFCCC and their regional counterparts | Academia 2 | Health facil- ities, health and agricul- ture extension workers |
| MOH, MOA, EFCCC and their regional counterparts | MOE and their regional coun- terparts | МОН, МОА | МОН, МОА |
| ന | | m | %08 |
| 2021– 2025 | 2022 onwards | 2021– 2025 | 2021– 2025 |
| Number of advocacy sessions | Antimicrobial resistance in- corporated into one or more clubs in selected schools | Number of job aids developed | Percentage of facilities integrating rational medicine use, antimicrobial resistance prevention and containment in their health education |
| Advocacy for inclusion of antimicrobial resistance-related topics in curricular and extracurricular activities | Inclusion of antimicrobial resistance and rational medicine use topics in extracurricular works (school health, nutrition programme and clubs) | Develop job aids for professionals to improve adherence to counselling in human and animal health care | Integrate antimicrobial resistance and rational medicine use into existing health education activities in waiting areas both in public and private facilities (education and mentoring) |
| Incorporate personal, public and food hygiene | and sanita- tion, nutrition, good farming and environ- ment health control prac- tices, related to the rational medicine use and antimicro- bial resistance in to school curricula and extracurricular activities | Raise aware- ness of clients | on rational use of antimi- crobials and adherence to treatment and profes- sional advice through health edu- cation and training |

| Develop and implement regular and need based | Conduct training on responsible prescribing, dispensing, use, and administration practices for human and animal health care professionals including for health and agriculture extension workers | Number of trainings provid- ed per year | 2021– 2025 | 15 per sector | МОН, МОА | Academia health facili- ties, EFCCC | 115 |
|--|---|---|---------------|--|---|---|-----------|
| pre-grad- uation and in-service training and continuous professional | Facilitate and provide a pre-graduation training on antimicrobial use, resistance and stewardship and infection prevention and control for human and animal health professionals | Percentage of higher education institutions providing pre-graduation training on antimicrobial use, resistance and stewardship and infection prevention and control | 2022– 2025 | 100% | Academia, MOH, MOA, EFCCC, MOSHE | MOE, profes- sional associ- ations | 1 000 |
| development programmes on antimicrobial use, resistance and stewardship and infection prevention and control, including for health and agriculture extension workers | Incorporate antimicrobial use, resistance and stewardship and infection prevention and control modules and trainings for human and veterinary professionals, including for health and agriculture extension workers | Number of professional associations that have incorporated antimicrobial resistance prevention and containment in their continued professional development training | 2022 | 1 per profes- sional associa- tion | MOH, MOA, professional associations | Academia | 27 125.00 |

| Initiative 1.3: Em ment | Initiative 1.3: Empower the media (public and private) and engage civil society organizations on antimicrobial resistance prevention and contain- ment | civil society organizations | s on antim | icrobial re | sistance preve | ntion and con | tain- |
|---|---|--|---------------------------------|-------------|--|---|--------------|
| Capacitate media and civil society on antimicro- | Provide trainings on antimicrobial resistance for media professionals (print and electronic) | Number of trainings provid- ed per year | 2021– 2025 | 10 | MOH, MOA, EFCCC and their regional counterparts | Media, civil society | 40 |
| o .≒ | Conduct advocacy workshops on antimicrobial resistance for civil society groups | Number of workshops provided | 2021– 2022, 2023– 2024 | 2 | МОН, МОА, ЕFCCC | Media, civil society | 15 000.00 |
| the public | Disseminate information on antimicrobial resistance to the general public through media and civil society | Number of media and civil society sessions on antimi- crobial resistance | 2021– 2025 | 50 | Media, civil society | MOH, MOA, EFCCC, Ethiopian Broadcasting Corporation | 14 750.00 |
| Initiative 1.4: Ad | Initiative 1.4: Advocacy and communication on antimicrobial resistance with policymakers and decision-makers | ance with policymakers ar | nd decision | ת-ה-hakers | | | |
| Advocate antimicrobial resistance as a national and | Conduct advocacy workshops | Number of advocacy work- shops | 2021– | m | National and regional Advisory Committees | MOH, MOA, EFCCC | 18 |
| | Develop policy briefing and disseminate them | Number of policy briefs disseminated | 2025 | м | National and regional Advisory Committees | МОН, МОА, ЕFCCС | 6 750,00 |
| Total | | | | | | 2 642 355.56 | 9 |

4.2 OBJECTIVE TWO: STRENGTHEN THE KNOWLEDGE AND EVIDENCE ON ANTIMICROBIAL USE AND RESISTANCE THROUGH SURVEILLANCE AND RESEARCH

Table 10 Detailed operational plan for objective two

| Strategic Interven- Act | Activities | Indicator | Time of Fre- | | Lead implement- | Collaborators | Indicative |
|-------------------------|------------|-----------|--------------|--------|-----------------|---------------|------------|
| tions | | | imple- | -uenb | er | | budget |
| | | | menta- | cy | | | (\$SN) |
| | | | tion | (with- | | | |
| | | | | in 5 | | | |
| | | | | years) | | | |

nitiative 2.1: Establish and strengthen surveillance on antimicrobial resistance priority pathogens in human and animal health, feed and food safety,

| | 1200.00 | 3 299 700,00 | 4 924 000.00 | 270 000.00 | 500 000.00 |
|---------------------------|---|---|--|---|---|
| | MOH, MOA AHRI, EFDA, EFCCC, National Veteri- nary Institute (NVI), stake- holders in the regional state, private diagnostic labs | EPSA, private pharmaceu- tical suppliers | мон, wно | Research institutes, devel- opment partners, media | Development partners |
| | EPHI, National Animal Health, Diagnostic and Investigation Center (NAHDIC), EEFRI | EPHI, NAHDIC, EEFRI | EPHI, NAHDIC | MOH, MOA, EFCCC and their agencies | MOH, MOA, EFCCC |
| - | _ | 30 | 2 | 2 | |
| - | 2021 | 2021-2025 | 2021–2025 | 2021–2025 | 2021-2022 |
| | Availability of joint plan | Number of antimicro- bial resistance sentinel sites | Number of program- matic antimicrobial resistance surveillance systems | Annual review meeting conducted | Established national antimicrobial resistance database |
| nent | Develop joint plan to establish surveillance system on antimi- crobial resistance | Establish and expand antimicro- bial resistance sentinel sites | Establish and strengthen programmatic antimicrobial resistance surveillance system for human and animal health | Organize an antimicrobial resistance data and information dissemination platform and review meeting | Establish an antimicrobial resistance database and generate reports among the human, animal and plant health, food safety and environment sectors |
| plant and the environment | Establish and strengthen antimicrobial resistance surveillance systems to detect and report antimicro- | bial resistance and disseminate information to facilitate | decision-making at all levels in all sectors. | | |

| Strategic interventions | Activities | Indicator | Time of imple-comenta- | Fre- quen- cy (with- in 5 | Lead implement- er | Collaborators | Indicative budget (US\$) |
|--|---|--|--|---------------------------------------|------------------------------|---|--------------------------------|
| Establish multi-in- | Create One Health antimicrobial resistance surveillance and | Platform created | 2021 | | EPHI, NAHDIC, AHRI, EEFRI | MOH, MOA, EFCCC, development partners, | 81 000.00 |
| to collate and channel surveil- | research platforms | Number of platform meetings conducted | 2022-2025 5 | -0 | | academia | |
| lance reports and case studies on antimicrobial resistance and informed | Generate and disseminate integrated antimicrobial resistance surveillance reports from all sectors | Number of joint reports and research articles disseminated | 2021–2025 5 | 10 | EPHI, NAHDIC, AHRI, EEFRI | MOH, MOA, EFCCC, development partners | 65 000.00 |
| policymaking and decision-making | Prepare policy briefs | Written policy briefs | 2021–2025 2 | | EPHI, NAHDIC, AHRI, EEFRI | MOH, MOA, EFCCC, development partners | 2700,00 |
| Establish a real-time patient- and population-based antimicrobial resistance | Conduct real-time patient- (human and animal) and population-based antimicrobial resistance surveillance | Number of real-time surveillance reports produced | 2021-2025 2 | | EPHI, NAHDIC, EEFRI | МОН, МОА, ЕГССС | 108 000,00 |
| surveillance system | Monitor antimicrobial resistance trends to demonstrate the extent of the problem in human, animal and plant health, food safety and the environment | Number of survey reports conducted | 2021-2025 5 | 10 | EPHI, NAHDIC, EEFRI | MOH, MOA, EFCCC | 27 000.00 |

| Strategic interventions | Activities | Indicator | Time of imple-menta-tion | Fre- quen- cy (with- in 5 | Lead implement- er | Collaborators | Indicative budget (US\$) |
|---|--|---|--------------------------|---------------------------------------|---|---|--------------------------------|
| Strengthen and maintain a national bio-repository on antimicrobial resistance priority organisms, strains and | Develop and disseminate a national bio-repository guidelines | Developed and disseminated biorepository guidelines | 2022-2023 | - | EBI, EPHI, NAHDIC, EEFRI AHRI, Animal Products, Veterinary Drug and Feed-Qual- ity Assessment Center (APVDF-QAC) | MOH, MOA, EFCCC, development partners, WHO | 13 500.00 |
| genes | Strengthen the existing national bio-repository (bio-bank) centre | Center strengthened | 2023–2025 | | EBI, EPHI, NAHDIC, EEFRI, AHRI, APVDF- QAC | MOH, MOA, EFCCC, development partners WHO | 2 000 000:00 |
| Establish an alert system on emerg- ing and re-emerg- ing antimicrobial | Develop protocols and guidelines for notifying of an antimicrobial resistance infection outbreak | Protocol and guidelines developed | 2022 | _ | EPHI, NAHDIC | МОН, МОА, ЕГССС | 6000.00 |
| resistance issues that have public and animal health emergency impor- tance | Generate alert report | Generated alert reports | 2021–2025 | Contin- uous | EPHI, NAHDIC, AHRI, APVDF- QAC | MOH, MOA, EFCCC | |

| Strategic interven- tions | Activities | Indicator | Time of imple-menta-tion | Fre- quen- cy (with- in 5 | Lead implement- er | Collaborators | Indicative budget (US\$) |
|--|--|---|--------------------------|---------------------------------------|--|--|--------------------------------|
| Initiative 2.2: Build up | Initiative 2.2: Build up the capacity for a quality management system of laboratories for human, animal and plant health, feed and food safety and | nagement system of la | aboratories | years) for huma | ın, animal and plant | health, feed and food s | afety and |
| Standardize micro-biology laboratory | Standardize micro- biology laboratory skills and knowledge | Assessment reports | 2021–2023 | 2 | EPHI, NAHDIC, EEFRI | MOH, MOA, EFCCC, diagnos- tic laboratories, academia, partners | 63 000.00 |
| and techniques, including advanced detection methods | Prepare a laboratory implementation plan based on the identified gaps (sample collection, transport, submission, processing and confirmatory testing, training, consumables and equipment) | Implementation plan executed | 2022 | <u></u> | EPHI, NAHDIC, EEFRI | MOH, MOA, EFCCC, development partners | |
| | Develop and review a laboratory sample referral system | Number of networked laboratories | 2022 | | EPHI, NAHDIC, EEFRI | MOH, MOA, EFCCC, development partners | 12 180,00 |
| | Develop and disseminate a national harmonized reference manual or guidelines on antimicrobial resistance-related tests | Availability of harmonized manual | 2021–2022 | | EPHI, NAHDIC, EEFRI | MOH, MOA, EFCCC, Ethiopi- an Standards Agency (ESA), health facilities, laboratories development partners | 21 120.00 |
| | Develop and conduct internal quality control | Number of antimicrobial resistance sites implementing internal quality control | 2021–2025 | 30 | EPHI, NAHDIC, EEFRI | MOH, MOA, EFCCC, develop- ment partners | ΨZ. |
| | Involve antimicrobial resistance surveillance sites in external quality assurance schemes | Number of antimicrobial resistance sites participating in external quality assurance schemes (three times per year) | 2021–2024 | 30 | EPHI, NAHDIC, EEFRI | MOH, MOA, EFCCC, develop- ment partners | 506 250.00 |
| | Facilitate external quality-assur- ance schemes proficiency testing panel production | Number of external quality assurance schemes panel production | 2025 | 2 | EPHI, NAHDIC | MOH, MOA, development partners | 1 297 662,00 |
| | Procure American-type culture collection strains | Uninterrupted internal guality control and con- firmatory tests | 2021–2025 | Continu- ous | EPHI, NAHDIC, Ethi- opian Environment and Forest Research Institute (EEFRI) | MOH, MOA, EFCCC, develop- ment partners | 501 000.00 |

| Strategic interventions | Activities | Indicator | Time of imple-menta-tion | Fre- quen- cy (with- in 5 | Lead implement- er | Collaborators | Indicative budget (US\$) |
|--|---|--|--------------------------|---------------------------------------|---|--|--------------------------------|
| | Establish a microbiology media preparation centre | Centre established | 2022-2025 | 3 | EPHI, NADHIC, AHRI, EEFRI, regional labo- ratories | MOH, MOA, EFCCC, devel- opment partners | 200 000'00 |
| | Implement a quality manage- ment system | Number of antimicrobi- al resistance sites im- plementing a laboratory quality-management system | 2021–2025 | 30 | Surveillance sites, EPHI, NAHDIC, EFCCC, EEFRI | MOH, MOA, EFCCC, development partners | 135 000.00 |
| | Ensure involvement of antimicrobial resistance surveillance laboratories in an accreditation system | Number of accredited Iaboratories | 2021–2025 | 10 | Surveillance sites, EPHI, NAHDIC, EFCCC, EEFRI | MOH, MOA, EFCCC, development partners | |
| Establish and strengthen laboratory facilities and equipment maintenance and calibration controls. | Conduct a feasibility study for strengthening the national calibration and metrology centre | Feasibility study conducted | 2022 | | EPHI, NAHDIC, EEFRI, National Metrology Institute of Ethiopia | MOH, MOA, EFCCC, development partners | 3000,00 |
| | Strengthen in-country equip- ment maintenance and cali- bration services at the national level | Avail of maintenance and calibration services at the national level | 2021-2025 | 5 | EPHI, NAHDIC, EEFRI | MOH, MOA, EFCCC, development partners | 90 000:00 |

| Strategic interventions | Activities | Indicator | Time of imple-menta-tion | Fre- quen- cy (with- in 5 | Lead implement- er | Collaborators | Indicative budget (US\$) |
|---|---|--|--------------------------|---------------------------------------|--|---|--------------------------------|
| Build up the capacity of human resources for specimen management, conducting culture, identification and antimicrobial sensitivity tests and reporting in relation to humans, animals, the environment and feed and food processing, using phenotypic and molecular methods | Develop training materials and provide training for professionals working at sentinel sites | Training provided | 2021–2025 | 2 | EPHI, NAHDIC, EEFRI | Surveillance sites, devel- opment partners | 45 000.00 |
| Strengthen the laboratory informa- | Assess the existing laboratory information system | Assessment report | 2022 | | EPHI, NAHDIC, EEFRI, health facilities, labo- | MOH, MOA, EFCCC, development partners | 6 300,00 |
| tion management systems | Establish a standardized labora- tory information system | Number of facilities with standardized laboratory information system | 2021–2025 | 15 | ratories | | 21 000.00 |

| Initiative 2.3: Basic a | Initiative 2.3: Basic and operational research | | | | | | |
|---|--|---|------------------|------------|--|--|------------|
| Conduct basic and operational research on an- timicrobial use, | Identify priority operational research areas | Identified operational research areas | 2022 and 2024 | 2 | MOH, MOA, EPHI, AHRI, NAHDIC, EFCCC, EEFRI, academia | Professional associations, EFDA, VDFACA | |
| consumption and resistance | Conduct research on prioritized areas (including burden and impact of antimicrobial resistance) and determining risk factors and drivers of resistance | Number of research studies conducted | 2022–2025 | F | EPHI, NAHDIC, EEFRI, AHRI, academia, APVDF- QAC, professional associations | MOH, MOA, EFCCC | 212 520.00 |
| | Conduct systematic review and meta-analysis of national studies on antimicrobial use, resistance and consumption and antimicrobial residue levels | Systematic review and meta-analysis conducted | 2023–2024 | 1 | EPHI, AHRI, NAH- DIC, EFDA, VDFA- CA, EEFRI | MOH, MOA, EFCCC, development partners | 7500.00 |
| Introduce innova- tive technologies and research for infection and an- | Assess innovative technologies and methods to introduce innovative rapid diagnostic techniques | Assessment report | 2022 | Once | Surveillance sites, EPHI, NAHDIC, AHRI, EEFRI, aca- demia | MOH, MOA, EFCCC, development partners | 30 000:00 |
| timicrobial resist- ance rapid diag- nostic tests and methods | Adopt new diagnostic tools, equipment, Number of point-of-kits and point-of-care devices and techniques (field-applicable rapid tests) | Number of point-of- care tests introduced | 2021–2025 | Continuous | | | 720 000.00 |

| Research on diag- nostics and treat- ment alternatives | Conduct research to introduce new and improved vaccines for humans and animals (pneumococcal vaccine) | Number research studies produced | 2021–2025 | 2 | EPHI, NAHDIC, EEFRI, NVI AHRI, academia, APVDF- | MOH, MOA, EFCCC, profes- sional associa- | 23 500.00 |
|---|--|--|-----------|--------------|---|--|------------|
| tor infections that can be treated with antimicrobials | Conduct research to identify rapid or best diagnostic methods and/or metrics to improve rational use of antimicrobials | Number of research studies produced | 2021-2025 | 0 | NAHDIC, academia af- d with referral tals | MOH, MOA, EPHI, NAHDIC, EFCCC, AHRI, APVDF-QAC professional associations | 100 000.00 |
| | Undertake joint vaccination assessment to identify gaps on selected human and animal diseases | Joint vaccination coverage assess- ment undertaken | 2023 | - | MOA, EPHI, AHRI | MOH, NVI, NAHDIC, their regional and city adminis- tration coun- terparts, health facilities | 7500.00 |
| Develop an AMR index to communicate gaps in antimicrobial effectiveness and help aggregate data | Identify key stakeholders | Stakeholders iden- tified | 2021-2025 | _ | МОН, МОА, ЕГССС | EEFRI, professional associations, EPHI, NAHDIC, AHRI, APVDF-QAC, academia | ∀ Z |
| on resistance to assess trends over time and across locations | Gather and disseminate AMR index | AMR index available | 2021–2025 | _ | EPHI, NAHDIC, EFCCC | мон, моа | 4500.00 |

| Initiative 2.4: Establis ance in the environm | Initiative 2.4: Establish and strengthen surveillance and res ance in the environment, plant, food and feed sectors | esearch on antimicr | obial contam | inants and | earch on antimicrobial contaminants and residues and the drivers of antimicrobial resist- | drivers of antim | icrobial resist- |
|---|---|---|--------------|-------------|---|---|------------------|
| Establish and strengthen surveillance and research of antimicrobial | Establish and strength- Establish national antimicrobial residue en surveillance and re-search of antimicrobial plant and food safety | System established | 2022 | _ | EFDA, VDFACA, EEFRI | MOH, MOA, EFCCC, EPHI, NAHDIC, AHRI | 7500.00 |
| waste in the environ- ment, plant and food sectors | Conduct research and surveillance on antimicrobial residues in food, effluents and waste | Number of research report produced | 2021–2025 | Ŋ | VDFACA, EFDA academia AHRI, EEFRI | MOH, MOA, EFCCC, EPHI | 45 000.00 |
| | Monitor the level of antimicrobial residues, based on the surveillance and research findings in food, manufacturing plants, health facilities, other institutions, individual households, waste from animals and slaughter houses | Number of mon- itoring activities performed | 2023–2025 | ന | VDFACA, EFDA, AHRI, EEFRI | MOH, MOA, EFCCC, EPHI, academia | 22 500.00 |
| | Identify priority foodborne pathogenic indicator bacterial species in animal, plant and aquatic origins | Data generated and reported | 2022–2023 | | AHRI, EPHI, NAH- DIC, EEFRI | MOH, MOA, EFCCC | 20 000.00 |
| Total | | | | | | | 15 034 132.00 |

4.3 OBJECTIVE THREE: ENHANCE INFECTION PREVENTION AND CONTROL THROUGH EFFEC-TIVE ENVIRONMENTAL HEALTH, INFECTION PREVENTION AND BIO-RISK MANAGEMENT IN HUMAN, ANIMAL AND PLANT HEALTH CARE

Table 11: Detailed operational plan for objective three

ive

0

0

9

| minance 3.1. Such guier and promote infection provention and control programmes to marian, animal and plant health and the environment | _ | | | | | | |
|--|---|---|--------------------------------|---------------------------------------|-----------------------|---|-------------------------------|
| Strategic interventions | Activities | Indicator | Time of implemen- tation | Fre- quen- cy (with- in 5 | Lead imple- menter | Collaborators | Indicativ budget (US\$) |
| Coordinate multisector collaboration to limit | Establish and strengthen multisector task force on infection prevention and control and hygiene | Multisector task force established at each level | 2021–2022 | 13 | MOH, MOA, EFCCC | Facilities, academia, development part- ners | 92 000'00 |
| the emergence, re-emergence and spread of antimicrobial resistance and multiple-drug | Develop guidelines for herd health packages, such as disease prevention and control, good husbandry practices, bio-risk management, effluents and manure, and waste disposal management | Guidelines developed | 2022 | ന | MOH, MOA, EFCCC | Health, agriculture and environment bureaus, universities, facilities, develop- ment partners | 68 400.00 |
| resistant organisms in humans, animals, plants and the environment | Organize platforms to identify, share and reward best practices on infection prevention and control | Number of events organized to share and reward best practices on infection prevention and control | 2021–2025 | ري ا | MOH, MOA, | Academia, research institutes, profession- al associations | 35 000.00 |

| Set and enforce standards on infection prevention and control practices as per One Health approach | Develop institutional infection prevention and control policies and standard protocols and monitoring tools, including herd disease prevention and control, good husbandry practices, bio-risk management and effluents, manure and waste disposal management | Developed infection prevention and control policies, protocols and tools | 2021–2022 | т | MOH, MOA, EFCCC | Health, agriculture and environment bureaus, facilities | 68 400.00 |
|---|---|--|-----------|--------------|---|---|-----------|
| | Enforce adherence to infection preven- Percentage of facilitication and control policies and standards ing to the standards | es adher- | 2022–2025 | 80 % | MOH, MOA and their regional counterparts | Facilities | 7500.00 |
| Develop pro- tocols and guidelines for infection out- | Develop case management protocols and guidelines for infection outbreaks due to antimicrobial resistance and multiple-drug resistant strains | Developed protocols and guidelines | 2021 | - | MOH, MOA and their regional counterparts | EFCCC, facilities | 6500.00 |
| break detection and case man- agement due to antimicrobial resistance and multiple-drug resistant strains | Print, disseminate and distribute out-break detection and case management protocols and guidelines protocols and guidelines | - | 2022 | - | MOH, MOA, and their regional counterparts | EFCCC, facilities | 5000.00 |

| Initiative 3.2: Stre | Initiative 3.2: Strengthen infection prevention and control practices in public and veterinary health facilities | ntrol practices in public and | d veterinary k | nealth fa | cilities | | |
|---|---|---|----------------|-----------|---|--|------------|
| Ensure imple- mentation of safe infection prevention and | Establish and strengthen a functional infection prevention and control committee at the human and animal health from and control committee | Percentage of facilities with functional infection prevention and control committee | 2021–2025 | 100% | Regional bureaus, human and animal health facilities | Regional bureaus, MOH, MOA, develop- 100 000.00 human and ment partners animal health facilities | 100 000.00 |
| control practices in human and veterinary health facilities | Promote the availability of infection prevention and control materials, supplies and equipment, including safe and adequate water supply in health facilities | Percentage of facilities with required infection prevention and control supplies | 2021–2025 | 80% | Health facilities, MOH, MOA and their regional counterparts | Ministry of Water Irrigation and Energy, suppliers | 50 000.00 |
| | Monitor the infection prevention and control practices at targeted facilities | Number of facilities moni- tored | 2021–2025 | 200 | MOH, MOA and their regional counterparts | EFCCC, health facil- ities, development partners | 25 000,00 |
| | Conduct in-service trainings on infection prevention and control | Number of trainings provided | 2021–2025 | 5 | MOH, MOA, and their regional counter parts, academia, professional associations | EFCCC, health facilities, development partners | 200 000.00 |

| human and vet- erinary health facilities infection prevention measures | | | | | meir regional counterparts | velopment partners | |
|---|---|---|-----------|--------------------------------|--|---|-----------|
| | ited | Percentage of health facilities with health care-associated infection prevention measures | 2021–2025 | 100% | Health facilities | MOH and regional counterparts, WHO, development part-ners | 87 500.00 |
| | | Percentage reduction of health care-associated infections | 2024 | 10% reduction from base- | Health facilities | MOH and regional counterparts, WHO, development partners | 12 250.00 |
| Implement clinic-a prevention measu facilities | Implement clinic-acquired infection prevention measures in animal health facilities | Percentage of health facilities with health care-associated infections prevention plan | 2021–2025 | 50% | MOA, region- al agriculture bureaus, animal health facilities | Development part- ners | |
| Strengthen prevention of zoonotic diseases | e and risk factors of | Surveys conducted | 2021 | | MOH, MOA, EFCCC | Health, agriculture and environment bureaus, universities | 34 200,00 |
| | Develop integrated zoonotic disease prevention and control action plan | Action plan developed | 2022 | | MOH, MOA, EFCCC | Health, agriculture and environment bureaus, universities | 11 400.00 |
| Design and implement collaborevidence-based interventions | orative | Number of interventions | 2022-2023 | 4 | MOH, MOA, EFCCC | Health, agriculture and environment bureaus, universities | 22 800.00 |
| Integrate zoonotic diseas through the One Health region and facility levels | se prevention approach at | Percentage of facilities and regions practising the One Health approach | 2021–2025 | 100% | МОН, МОА, ЕFCCC | Health, agriculture and environment bureaus, universities | 45 000.00 |

| Initiative 3.3: Stre | Initiative 3.3: Strengthen good animal husbandry practices | ctices | | | | | |
|---|--|--|-----------|--------------|---|---|-----------|
| Promote bio-risk management and good hus- | Prepare necessary regulations and legislation related to intensive and extensive farms | Legislation prepared and endorsed | 2021–2023 | | MOA | Regional counter- parts, facilities, devel- opment partners | 15 000.00 |
| bandry practi ces | Conduct situation analysis in the food value chain (meat, milk, honey) for prioritized five species, agro-ecology (low, mid and high land) | Situation analysis conducted | 2021 | - | MOA | Regional counter- parts, facilities, devel- opment partners | 34 200.00 |
| | Conduct assessment of knowledge, attitudes, behaviour and practices on good husbandry practice | Assessment done on knowledge, attitudes, behaviour and practices | 2021 | _ | MOA, private sector, individual farmers | Regional agriculture bureaus, facilities, de- velopment partners | 34 200.00 |
| | Develop bio-risk guidelines for animal feed processing and poultry, dairy and beef production, food handlers and traders | Guidelines developed | 2022 | - | MOA, EFDA | Regions, facilities, development part- ners, private sector, farmers | 22 800.00 |
| | Implement biosecurity guidelines in selected farm production systems | Number of production systems implementing biosecurity guidelines | 2022-2025 | °C | MOA | Regions, facilities, development part- ners, private sector, farmers | 35 600.00 |
| | Improve awareness on good animal feed production (harvesting, distribu- tion and storage) and cleanliness of the yard | Number of training sessions | 2021–2025 | 2 | MOA | Regions, facilities, development part- ners, private sector, farmers | 87 500.00 |
| | Promote integrated legal obligations regarding animal welfare in the annual action plan | Integrated legal obligation regarding animal welfare in the annual action plan | 2021–2025 | 2 | MOA | Regions, facilities, development part- ners, private sector, farmers | 34 700.00 |
| | Promote and disseminate selective breeding (disease resistant breeds) | Types of disease-resistant breeds disseminated | 2021–2025 | D. | MOA | Regions, facilities, development part- ners, private sector, farmers | 84 900.00 |

| Integrate antimicrobial resistance prevention | Improve vaccination service coverage, supply and cold chain management | Percentage coverage | 2021–2025 | 80% | MOA | Regions, facilities, development partners | 42 400.00 |
|--|--|------------------------------------|--------------|-----------|--|--|-----------|
| and contain- ment activities with veterinary outreach servic- | Improve outreach services | Percentage coverage | 2021–2025 | %08 | Animal health workers, community animal health workers | Regions, facilities, development partners | 30 300.00 |
| es and vaccina- tion access | Conduct staff capacity-building | Number of trained trainers | 2021–2025 | 200 | MOA | Regions, facilities, development partners | 49 000'00 |
| | | | | | | | |
| Initiative 3.4: Pron | Initiative 3.4: Promote personal hygiene and strengthen water, sanitation and hygiene (WASH) services at the community level | nen water, sanitation and hy | /giene (WASI | 4) servic | es at the commu | nity level | |
| Promote personal and environmental hygiene and sanitation | Support and enforce human and ani- mal health facilities to provide function- al handwashing and bathing facility for staff and patients | SS | 2021–2025 | 100% | Health facilities | MOH, regional health 10 500.00 bureaus, WHO | 10 500.00 |
| | Support facilities to prepare and dispense alcohol-based hand sanitizer | Percentage of facilities supported | 2021–2025 | 100% | MOH, MOA, EFCCC and their regional counter- parts | Health facilities, de- velopment partners | 10 500.00 |

| Promote, implement and enforce proper waste manage- | Promote and enforce safe human excreta disposal and functional improved latrines in communities | Percentage of community settings with functional improved tollets with handwashing provision | 2021–2025 | %09 | MOH, MOA, EFCCC and their regional counter- parts | UNICEF, FAO, WHO, health facilities, com- munity leaders | 15 500.00 |
|--|--|---|-----------|------|--|---|-----------|
| ment at the community level | Promote and enforce functional seepage pits, septic tanks and oxidation pond connected with a sewer line in health facilities | Percentage of health facilities with functional and proper liquid waste management | 2021–2025 | 100% | MOH, Ministry of Water Irrigation and Energy | Regional health bureaus, Women Support Association, WHO, health facilities | 10 500.00 |
| | Promote and enforce to have functional incinerator, refuse pits and solid waste collection bins | Percentage of health facilities with functional and proper solid waste management | 2021–2025 | 100% | MOH, Ministry of Urban De- velopment and Housing | Regional health bu- reaus, WHO, health facilities | 10 500.00 |
| | Promote and enforce hazardous waste management in health facilities | Percentage of health facilities with functional and proper hazardous waste management | 2021–2025 | 100% | MOH, Ministry of Urban De- velopment and Housing | Regional health burreaus, WHO, health facilities | 10 500.00 |
| Encourage and promote safe water supply and sanitation services for humans and animals | Build up the capacity of health and agricultural extension workers to encourage and promote clean home environments, school compounds and animal housing | Number of capacity en- hancements provided for health and agricultural exten- sion workers | 2021-2025 | 10 | мон, моа | EFCCC, regional health bureaus, regional agriculture bureaus, WHO, FAO | 31 500.00 |

| Initiative 3.5: Stree | Initiative 3.5: Strengthen information system for infection | tion prevention and control management | I manageme | int 1 | ▼ OW H OW | Realians | 00000 |
|--|---|---|------------|----------|---|---|-----------------|
| Develop a multisector infection prevention and control information and communication management system | Develop and adopt an infection prevention and control information communication and management database | Database In place | 707-1707 | _ | MOH, MOA, EFCCC | regional labs, regional health bureaus, health fa- cilities, development partners | 000'00 |
| | Integrate notification of antimicrobial resistance and multiple drug-resistant infections into existing reporting systems | Number of reports produced | 2021–2025 | 2 | MOH (EPHI, AHRI), MOA (NAHDIC, VDFA- CA) | Regional labs, health facilities, develop- ment partners | 12 600.00 |
| Generate and disseminate evidence-based information to improve infec- | Conduct and disseminate operational research on infection prevention and control practices | Number operational research studies conducted | 2021–2025 | ೮ | MOH (EPHI and AHRI) MOA (NAHDIC) | Regional labs, regional health bureaus, health facilities, development partners | 37 500.00 |
| tion prevention and control practices and decision-making processes | Disseminate and use the information for decision-making | Number of compiled information reports disseminated | 2021–2025 | Ŋ | MOH, MOA, EFCCC | Health, agriculture and environment bureaus | |
| Total | | | | | | | 1 526 023.30 |

4.4 OBJECTIVE FOUR: OPTIMIZE THE USE OF ANTIMICROBIALS IN HUMAN, ANIMAL AND PLANT HEALTH CARE

Table 12: Detailed operational plan for objective four

| Initiative 4.1: Improve a | Initiative 4.1: Improve access to quality antimicrobials and I | laboratory supplies in the human and animal health sectors | e human and | animal | nealth sectors | | |
|--|--|---|--------------------------------|---------------------------------------|--|--|-------------------------------------|
| Strategic interventions Activities | Activities | Indicator | Time of implemen- tation | Fre- quen- cy (with- in 5 | Lead imple- menter | Collaborators | Indic- ative budget (US\$) |
| Ensure an effective supply chain management of quality essential antimicrobials and laboratory | Assess prioritization of essential antimicrobials and laboratory supplies in the government and non-government procurement list for human and animal health sectors | Assessment reports | 2021 and 2024 | 2 | MOH, MOA, EPSA, EPHI, NAHDIC, EHIA, AISCO | Development partners, EFDA, VDFACA | 25 000.00 |
| supplies | Advocate inclusion of priority antimicrobials and laboratory supplies in the Ethiopian Pharmaceuticals Supply Agency (EPSA) and the Agriculture Inputs Supply Corporation (AISCO) long-term procurement agreements and/or non-government suppliers | Antimicrobial and laboratory supplies included in suppliers' long-term procurement agreements | 2021–2025 | Continuous | MOH, MOA, EPSA, AISCO | Private manufacturers, importers, distributors | 17 500.00 |
| Promote local production of quality antimicrobials and laboratory supplies | Undertake a baseline assessment of local manufacturing capacity | Assessment report | 2021 | | MOH, MOA, MOTI, Ethiopian Invest- ment Commission (EIC) | EFDA, VDFACA | 5250.00 |
| for human and animal | for human and animal Advocate capacity enhancement of local manufacturers | Number of advocacy campaigns conducted | 2021–2025 | က | МОТІ, МОН, МОА, ЕІС | | 7200.00 |

| Initiative 4.2: Ensure opt | Initiative 4.2: Ensure optimal prescribing, dispensing and use of antimicrobials in the human health sector | se of antimicrobials in th | le human hea | Ith sect |)r | | |
|---|---|---|--------------|-------------|--|--|---------------|
| Integrate antimicrobial stewardship into the Hospitals | Conduct workshop for policymakers and decision-makers at all levels | Number of advocacy campaigns conducted | 2021 | 2 | MOH, regional health bureaus | Health facilities, development partners | 14 000.00 |
| Services Transforma- tion Guideline and the Ethiopian Health Center Reform Imple- mentation Guideline | Inclusion of antimicrobial stewardship into the Hospitals Services Transformation Guideline and the Ethiopian Health Center Reform Implementation Guideline | Antimicrobial stewardship included in the Hospitals Services Transformation Guideline and the Ethiopian Health Center Reform Implementation Guideline | 2022 | | MOH, regional health bureaus | Health facilities | 6250.00 |
| Ensure implementa- tion of a ntimicrobial stewardship in health care facilities | Ensure antimicrobial stewardship as one of health care facility managements' quality improvement parameters | Number of facilities with plan, dedicated budget and personnel for antimicrobial stewardship | 2021–2025 | 150 | | WHO, develop- ment partners | 33 000.00 |
| | Streamline antimicrobial stewardship into the existing pharmacy services (clinical pharmacy and the Drug Information Services) | Number of facilities with integrated Antimicrobial Stewardship Programme with clinical pharmacy services and the Drug Information Services | 2021-2025 | 150 | Health care facil- ities | MOH, regional health bureaus, development partners, WHO | ∢ Z |
| | Provide training on antimicrobial stewardship for the Antimicrobial Stewardship and the Drug and Therapeutic Committees and other professionals | Number of training sessions | 2021–2025 | 71 | MOH, regional health bureaus, EPHI, EFDA | Health care facilities, academia, WHO, development partners, professional associations | 210 |
| | Monitor implementation of functional antimicrobial stewardship at health care facilities | Number of health facilities that have implemented functional antimicrobial stewardship | 2021–2025 | 150 | MOH, regional health bureaus | | 50 000,00 |

| Ensure the availability and monitor compliance with updated and evidence-based guidelines, policies, manuals and formularies for prescribing and dispensing practices | Review existing antimicrobial stewardship guidelines, prescribing and dispensing manuals, formularies and standard treatment guidelines and the WHO Essential Medicines List with the AWaRe classification of antibiotics Avail of and monitor compliance with evidence-based standard treatment guidelines and antimicrobial stewardship guidelines, prescribing and dispensing manuals, formularies and the WHO Essential Medicines List with the | Availability of updated evidence-based standard treatment guidelines, antimicrobial stewardship policy, prescribing and dispensing manuals, formularies and the WHO Essential Medicines List | 2021 | Continuous | MOH, regional health bureaus, EFDA, health facilities MOH, regional health bureaus, EFDA, health facilities | WHO, develop- ment partners, academia, professional associations WHO, develop- ment partners, academia, professional associations | 18 000.00 |
|---|---|--|-----------|--|---|--|---------------|
| Strengthen antimicrobial use and consumption surveillance for action to improve health care outcome | aware classification of antibiotics Conduct regular antimicrobial use and consumption surveillance at the health facility level | Percentage of health facilities conducting antimicrobial use and consumption surveillance | 2021–2025 | Yearly per health facility level | Health facilities | MOH, regional health bureaus, WHO, develop- ment partners | 63 000.00 |
| at the health facility and national levels | Conduct antimicrobial use and consumption surveillance at the national level | Number of antimicrobial use and consumption surveillance reports | 2021–2025 | 2 | MOH, regional health bureaus | Facilities, WHO, development partners | 125 000.00 |
| | Disseminate and ensure use of the evidence generated for improving health care outcomes, policymaking and decision-making process | Number of health care facilities utilized the antimicrobial use and consumption surveillance data for action | 2021-2025 | Contin- uous | MOH, regional health bureaus, health facilities | WHO, develop- ment partners | |

| Improve communica- tion and team prac- tices among health care providers | Organize multidisciplinary events (seminars, trainings, consultative meetings, morning sessions) on antimicrobial use and resistance | Number of events per year | 2022-2025 | 9 | Health facilities | MOH, regional health bureaus, academia | 240 |
|---|--|--|--------------|-------------|---|---|-----------|
| | Develop and disseminate up-to-date and unbiased scientific information on antimicrobial use and resistance | Number of materials disseminated (information and education communication materials, journal clubs, etc.) per year | 2021-2025 | 9 | Health facilities | MOH, regional health bureaus, academia | 15 000.00 |
| Initiative 4.3: Ensure op | Initiative 4.3: Ensure optimal prescribing, dispensing and us | se of antimicrobials in the animal health sector | e animal hea | Ith secto |)r | | |
| Develop guidelines relevant to the prudent use of antimi- | Develop prescription guidelines | Developed guideline | 2021 | | MOA, VDFACA and its counterparts | FAO, OIE, veter- inarian associa- tions | 20 000'00 |
| crobials | Review veterinary drug formulary | Updated formulary | 2021 | _ | MOA, VDFACA and its counterparts | FAO, OIE, associ- ations | 18 000,00 |
| | Dissemination of prescription guidelines, veterinary standard treatment guide-lines and formulary | Percentage availability of prescription guideline, veterinary standard treatment guidelines and formularies at veterinary facilities | 2021-2025 | %06 | MOA, VDFACA and its counterparts | FAO, OIE, associations | 2000,00 |
| Develop and pro- mote implementation of antimicrobial stew- | Develop antimicrobial stewardship guidelines for animal health facilities | Developed guidelines | 2021 | | MOA, regional agriculture bureaus, veterinary clinics | NAHDIC, VDFA- CA, academia | 20 000,00 |
| ardship in veterinary services | Implement antimicrobial stewardship in selected animal health facilities | Number of health facilities implementing antimicrobial stewardship | 2021–2025 | 15 | MOA, regional agriculture bureaus, veterinary clinics | NAHDIC, VDFA- CA, academia | 21 000.00 |

| Strengthen the diagnostic capacity of veterinary health services to promote | Equip the laboratory diagnostic testing in animal health facilities with materials and procedures | Number of laboratory facilities equipped with diagnostic testing materials and procedures | 2021–2025 | 20 | MOA, regional agriculture bureaus, veterinary clinics, VDFACA, NAHDIC | Academia, FAO, OIE | 1250 |
|---|--|---|-----------|-----------------|---|---|------------|
| rational antimicrobial use | Build up the capacity of human resources for quality laboratory diagnostic testing | Number of professionals trained | 2021–2025 | 150 | MOA, regional agriculture bureaus, Veterinary clinics, VDFACA, NAHDIC | Academia, FAO, OIE | 100 |
| Strengthen antimicrobial use and consumption surveying for veterinary health | Conduct regular antimicrobial use and consumption surveys at national and animal health facility levels | Number of surveys conducted | 2021-2025 | ري ا | MOA, regional agriculture bureaus, VDFACA, NAHDIC | Veterinary clinics | 75 000,00 |
| services | Use and disseminate survey data on antimicrobial use and consumption for policymaking and decision-making | Number of policy briefs disseminated | 2021-2025 | m | MOA, regional agriculture bureaus, VDFACA | NAHDIC, veteri- nary clinics | |
| Strengthen professional, farmers field school and animal owner communications to optimize antimicrobial use and consumption | Organize multidisciplinary events (trainings, farmers monthly meetings, vaccine campaigns, etc.) to empower animal owners on recording of animal history, disease trends and antimicrobial use and consumption | Number of events | 2021–2025 | 5 per region | MOA, regional agriculture bureaus, VDFACA, profes- sional associations | Farmers asso- ciations, unions, community animal health workers | 96 000,000 |
| | Ensure counselling of clients (animal owners) on adherence, withdrawal period of antimicrobials and antimicrobial resistance | Number of counselled animal owners | 2021–2025 | Contin- uous | Veterinary clinics | MOA, regional agriculture bu- reaus, VDFACA | 1200.00 |

| Initiative 4.4: Strengther | Initiative 4.4: Strengthen diagnostic stewardship at the health care facility level | th care facility level | | | | | |
|---|---|---|-----------|---|---|--|-----------|
| Build up capacity and standardize diagnostic laboratories | Undertake baseline assessment on microbiology laboratory services | Assessment report | 2021 | _ | EPHI, MOH, MOA, regional health bureaus, regional agriculture bureaus | Health facilities | 31 500.00 |
| | Develop diagnostic stewardship guide- lines | Guidelines developed | 2022 | | ЕРНІ, МОН, МОА | Regional health bureaus, regional agriculture bureaus, health facilities, WHO, FAO, OIE, CDC, United Nations Environment Programme, development partners | 6500.00 |
| | Provide trainings on diagnostic steward- ship for health care professionals | Number of training sessions conducted | 2022-2025 | 5 | EPHI, MOH, MOA, regional health | WHO, FAO, OIE, CDC, UNEP | 00'000 09 |
| | Organize experience-sharing visits local and abroad among laboratories | Number of experi- ence-sharing visits conducted | 2022-2025 | ſΩ | bureaus, regional agriculture bureaus | Development partners | 38 000.00 |
| Ensure generation and utilization of an- tibiogram data at the | Generate, review and disseminate facili- ty-specific antibiogram data | Number of health facilities generating antibiogram data | 2021–2025 | 30 | Health facilities, MOH, regional health bureaus | thampooling the transfer of th | |
| human health care facility level | Ensure use of antibiogram data at the health care facility level on a regular basis | Number of facilities using antibiogram data | 2021–2025 | 30 | Health facilities, MOH, regional health bureaus | partners | |
| Ensure prescribing practices of antimi- crobials based on laboratory diagnostic results | Promote real-time utilization of microbiological and other diagnostic results for prescribing practices | Number of consultative meetings conducted | 2021-2025 | 2 events per facility per year | MOH, regional health bureaus, health facilities | | 0 |

| Initiative 4.5: Strengther | Initiative 4.5: Strengthen the regulatory system in the human, animal, food and feed production and the environment sectors | n, animal, food and feec | d production | and the | environment sect | ors | |
|--|---|--|---------------|-----------------|--|---|---------------|
| Review, develop and enforce legislation on the prudent use of antimicrobials and | Develop, update and enforce legal frameworks for antimicrobials and laboratory supply use | Developed and updated human and animal health legal frameworks | 2021 and 2022 | | EFDA, VDFACA and their counterparts | MOH, MOA, regional health bureaus, region- al agriculture bureaus | 15 300.00 |
| laboratory supplies | Restrict and ban non-therapeutic use of antimicrobials in animal production and food production | List of restricted and banned antimicrobials | 2021–2022 | | MOA, VDFACA and their counterparts | FAO, OIE | 10 500.00 |
| Strengthen pre- and post-market surveil- | Review and develop systems and guidelines for market surveillance and control | Developed system for mar- ket surveillance | 2021 and 2022 | 2 | EFDA, VDFACA and their counterparts | FAO, OIE, WHO, development partners | 14 000.00 |
| lance and control of antimicrobials and laboratory and infec- tion prevention and control supplies | Conduct market surveillance and control | Number of market surveil- lance report | 2021–2025 | 4 | EFDA, VDFACA, and their counterparts | FAO, OIE | 92 750.00 |
| Build up capacity of regulatory bodies to ensure availability and use of quality | Assess the existing capacity of the regulatory bodies towards ensuring the availability and utilization of quality-assured antimicrobials, laboratory commodities and infection prevention and control supplies | Assessment reports | 2021 | 2 | EFDA, VDFACA | Regional coun- terparts of EFDA, VDFACA | 31 500.00 |
| antimicrobials, labo- ratory and infection prevention and con- trol supplies | Enhance capacity of human resources through needs-based training | Number of trainings pro- vided | 2021–2025 | 5 | EFDA, VDFACA and their regional coun- terparts | Development partners | 52 500.00 |
| Regulate food and feed preparation pro- cessing and dispensa- | Conduct regular inspection at all levels | Regular inspections conducted | 2021–2025 | Contin- uous | EFDA, VDFACA and their regional counterparts | Development partners | 150 000.00 |
| ry centres to enhance food and feed hy- giene and safety | Conduct hazard analysis of critical control points | Number of facilities conducting hazard analysis of critical control points | 2021-2025 | 5 | EFDA, VDFACA, MOA, MOH, EPHI | Development partners | |

| Ensure proper disposal of unfit-for-use antimicrobials and laboratory supplies | Establish and strengthen disposal facilities | Number of disposal facilities | 2021–2025 | 12 | MOH, MOA, EFDA, VDFACA, EFCCC, EPSA and their counterparts | Health facilities | ∀Z |
|--|--|---|-----------|-----------------|---|-------------------------|-----------------|
| · | Ensure proper disposal of unfit-for-use antimicrobials and laboratory supplies | Percentage of unfit- for-use antimicrobials and residues properly disposed | 2021–2025 | Contin- uous | MOH, MOA, EFDA, VDFACA and their counterparts, health facilities | Health facilities | ۲ ۲ |
| Establish standards for waste discharge | Develop and promote guidelines for waste disposal, discharge and treatment | Guideline available | 2022 | | MOH, MOA, EFCCC | Development partners | 18 000'00 |
| and treatment from manufacturing and food processing plants and human and animal health care settings | Monitor waste disposal and discharge practices at manufacturing and food processing plants and human and animal health care settings | Improved practice of waste disposal, discharge and treatment | 2022-2025 | Contin- uous | EFDA, VDFACA, EFCCC | Development partners | 0 |
| Establish predicted no-effect environ-mental concentration | Establish standard for minimum selective concentration and predicted no-effect concentration values | Availability of the predicted no-effect concentration standards | 2023 | | MOH, MOA, EFCCC | Development partners | 0 |
| values for resistance selection | Promote and monitor the established predicted no-effect concentration values | Low level of environmen- tal health risks | 2024–2025 | Contin- uous | МОН, МОА, ЕГССС | Development partners | 0 |
| Total | | | | | | | 2 980 450.00 |

ALLIANCES, GOVERNANCE AND RESOURCE MOBILIZATION AT ALL LEVELS 4.5 OBJECTIVE FIVE: STRENGTHEN AND ESTABLISH PARTNERSHIPS,


Table 13: Detailed operational plan for objective five

| | | ors Indicative ative budget (US\$) | ia- | 0 | .) 10 000.00 s, | . 52 500.00 - ia- |
|---|--|---------------------------------------|---|---|---|--|
| | | Collaborators | Development partners, aca- demia, associa- tions | Development partners, WHO | UNICEF, WHO, CDC, develop- ment partners, academia, associations | Development partners, aca- demia, associa- tions |
| | all levels | Lead imple- menter | MOH, MOA, EFCCC and their regional counterparts, institutions | MOH, MOA, EFCCC | MOH, MOA, EFCCC and their regional counterparts, institutions | MOH, MOA, EFCCC, Adviso- ry Committees, thematic work- |
| | zations at a | Fre- quency (within 5 years) | 35 | | 36 | 65 |
| | d resource mobiliz | Time of imple- mentation | 2021 and 2022 | 2021–2025 | 2021–2022 | 2021–2025 |
| | , alliances, governance and resource mobilizations at all levels | Indicator | Number of functional inter-ministerial committees, AMR Advisory Committees and thematic working groups | Functional and multidiscipli- nary AMR secretariat put in place | Number of AMR teams or focal points put in place | Number of review meetings conducted |
| _ | Initiative: 5.1: Strengthen and establish partnerships, al | Activities | Establish and strengthen a mul- ti-institution and multidisciplinary inter-ministerial committees, AMR Advisory Committees and themat- ic working groups at national and regional levels | Strengthen AMR secretariat at the national level (human resources, materials, finances, structures, etc.) | Establish and strengthen AMR team and focal points for human, animal, plant, water, sanitation, hygiene and wastewater management at different levels | Organize annual joint review meet- ings on the implementation of the national antimicrobial resistance operational plan |
| | Initiative: 5.1: Strer | Strategic inter- ventions | Strengthen the governa nce structure and | collaboration of national and regional antimi- | crobial resistance stakeholders | |

| Strengthen collaboration with multilateral and bilateral organizations engag- | Create platforms (networking, coordination, information and resource exchange mechanism) with all multilateral and bilateral antimicrobial resistance stakeholders | Number of coordination meet- ings conducted | 2021-2025 | D. | MOH, MOA, EFCCC | Development partners, Advisorry Committees, thematic working groups, academia, associations | 10 000.00 |
|--|--|--|-----------|-------------|--|---|-----------|
| ing in antimicro- bial resistance prevention and containment | Share information, knowledge and reports on antimicrobial resistance with international collaborators | Number of antimicrobial resistance research outputs, guidelines and surveillance, including Tripartite AMR Country Self-Assessment Survey reports shared | 2021-2025 | C) | AMR secretariat, MOH, MOA, EFCCC, EPHI, NAHDIC, EFRI | Development partners, aca- demia, associa- tions | 0 |
| Promote pub- lic-private partnerships | Develop public-private partnership framework on antimicrobial resistance prevention and containment | Framework developed | 2021/22 | | MOH, MOA, EFCCC, MOF | Development partners, aca- demia, associa- tions | 15 400,00 |
| on antimicro- bial resistance prevention and containment | Conduct regular advocacy platforms to engage the private sector on antimicrobial resistance prevention and containment | Number of advocacy platforms conducted | 2021-2025 | 10 | MOH, MOA, EFCCC and agencies under them, private organizations in the health sector | Development partners, aca- demia, associa- tions | 38 500.00 |
| Initiative 5.2: Strengthen leadership | ngthen leadership | | | | | | |
| Ensure leader- ship, ownership and commitment for su stainable | Incorporate antimicrobial resistance prevention and containment activities in the annual institutional plan and national strategic health plan | Number of institutions that have in- corporated antimicrobial resistance into their annual plan | 2021–2025 | 189 | MOH, MOA, EFCCC and their regional counter- parts, all stake- holders | National Planning Commission, devel- opment partners | |
| implementation of antimicrobial resistance stra- tegic plan at all | Allocate resources for the sustainable implementation of antimicrobial resistance activities | Number of institutions that have allocated resources | 2021–2025 | 189 | MOH, MOA, EFCCC and their regional counter- parts, all stake- holders | Ministry of Finance and regional coun- terparts, develop- ment partners | 0 |
| sectors | Conduct annual institutional antimicrobial resistance performance review meetings at the national level | Number of sectors that have conducted performance reviews | 2021-2025 | 15 | MOH, MOA, EFCCC, all stake- holders | Development partners | 63 000.00 |

| Initiative 5.3: Resource mobilization | urce mobilization | | | | | | |
|--|--|---|-----------|-------------|---|--|---------------|
| Ensure availabil- ity of sustaina- | Develop resource mobilization strategies | Resource mobilization strategy developed | 2021 | | AMR secretar- iat MOH, MOA, EFCCC | Development partners, MOF, aca- demia, associations | 15 080.00 |
| ble resources | Generate evidence on the return of investment in antimicrobial resistance prevention and containment | Number of evidence reports generated | 2024 | _ | MOH, MOA, EFCCC | Development partners, academia, associations | 20 000.00 |
| Ensure resource mobilization to encourage inno- | Mobilize resources for the development of new antimicrobials, vaccines, diagnostics, novel therapies and/or alternatives | Amount of resources mobilized and allocated for innovations | 2021–2025 | 100% | МОН, МОА | EFCCC, develop- ment partners, aca- demia, associations | 12 100.00 |
| vations on the development of new antimicrobials, vaccines, diagnostics, novel therapies and/or alternatives | Design incentive-based mechanisms to motivate sectors in the development of new antimicrobials, vaccines, diagnostics, novel therapies and/or alternatives | Incentive mechanisms in place | 2021-2025 | 1 | MOH MOA EFCCC | Development partners, academia associations, private sector | 10 000.00 |
| Total | | | | | | | 246 580.00 |
| Grand total for o | Grand total for objectives one-five in US\$ | | | | | 22 42 | 22 429 540.86 |

5. MONITORING AND EVALUATION FRAMEWORK



5. MONITORING AND EVALUATION FRAMEWORK

Implementation of the antimicrobial resistance prevention and containment interventions must be monitored regularly to enable a better understanding of the scope of the problem throughout the country as well as to measure any progress. Such monitoring requires the collection, collation, analysis and management of data from the human, animal, plant and environment sectors. Monitoring and evaluation help to extract relevant information from ongoing activities that can be used for programme fine-tuning, reorientation and future planning.

The role of monitoring and evaluation is to provide a strategic link with the relevant stakeholders to ensure that strategies are effective in responding to the antimicrobial resistance threats in the country. Additionally, it enables problems to be detected early, thereby reducing the likelihood of major cost overruns or time delays and related health outcomes.

A monitoring and evaluation system needs to be in place to ensure that results are reported in a timely and efficient manner. In addition, the system supports the establishment of transparent feedback loops with implementing agencies, stakeholders and the public.

The monitoring and evaluation framework of the third strategic plan will include:

Standard reporting systems (reporting template, line of communication, frequency of reporting).

Routine and periodic monitoring mechanisms, such as supportive supervision and regular review meetings.

Baseline, midterm and terminal evaluations (based on the key performance indicators stipulated in table 15).

The logic model for the antimicrobial resistance prevention and containment monitoring and evaluation framework is presented in figure 2.

5.1 LOGIC MODEL FOR THE NATIONAL ANTIMICROBIAL RESISTANCE PREVENTION AND **CONTAINMENT STRATEGIC PLAN**

Figure 2 Logic model for the National Antimicrobial Resistance Prevention and Containment Strategic Plan

| | | Roduction | and contains | ment of antimicrohia | rocietano | ģ | | S | |
|--------------------------------------|------------------|--|---|---|------------------------------|--|--|--|---|
| | IIIIpact | Deduction | ו מוום כסוונמוווו | Neducuon and containnent of anumicropial resistance | וובאוארשווו | ט | | • | Γ |
| | | | | | | | | stn9 | |
| Effec- tiveness | Outcome | Improved understan microbial ance in ta | Improved awareness & understanding of antimicrobial use & resistance in target groups | Strong multisector collaboration | | Reduced incidence of infection | Optimized use of antimicrobials | hns -blodə mssəsss bəs bəssd-noitsl | luations and g |
| | Ų. | | | | | | | ck-ps | nal eva |
| Quality | Out put | Survey & research report | Survey & Availabili- research ty of mi- report cro-biology & quality control lab | Availability of advocacy materials | Trained person- nel | AMR data- base | AMR in curriculum | | ıfi bns mrətbim ,a |
| | Ų. | | | | | | | | gnit |
| Leader- ship & govern- ance | Input & process | Budget | Facilities, premises | Development of information & education communication & behaviour change communication materials | Aware- ness & training | Legal instru- ments & guidelines | Human resources, leadership & political commitment | vument reviews, surv orts, administrative r | ular review at different isory Committee mee orting through the Glo |
| | | Governan | ice, multisecto | Governance, multisector collaboration | | | | | ٧ÞA |
| Driver⊕ | D omain ⊕ | Monitorir | ng & evaluation | Monitoring & evaluation framework for antimicrobial resistance | imicrobial | resistance | | Data source | Analysis & use |
| | | | | | : | . (| | | |

Figure 6: Logic model for the National Antimicrobial Resistance Prevention and Containment Strategic Plan

5.2 MONITORING AND EVALUATION PLAN

Table 14 Monitoring and evaluation operation plan

| Strategic interven- tions | Activities | Indicator | Time of imple-menta-tion | Fre- quency (within 5 years) | Lead imple- menter | Collabo- rators | Indic- ative budget (US\$) |
|--|---|-------------------------------------|--------------------------|---------------------------------------|--|---|-------------------------------------|
| Develop and implement monitoring and evaluation (M&E) guidelines | Develop M&E guide- lines with standard reporting template | M&E guide- lines devel- oped | 2021 | 1 | AMR secretariat | MOA, EFCCC | 15 000.00 |
| | Submit reg- ular imple- mentation reports at all levels | Number of timely reports | 2021– 2025 | Quarterly | MOH, MOA, EFCCC and their regional counter- parts | Devel- opment partners | NA |
| | Provide feedback | Timely feed- back | 2021– 2025 | Quarterly | AMR secretariat | MOH, MOA, EFCCC and their regional counter- parts, de- velopment partners | NA |
| Establish and strengthen routine and periodic monitoring | Organize integrated supportive supervision at all levels | Number of supervision report | 2021– 2025 | Biannual | MOH, MOA, EFCCC and their regional counter- parts | Devel- opment partners | 120 000.00 |
| mechanisms | Conduct an annual review meeting | Number of review meetings conducted | 2021– 2025 | Annual | MOH, MOA, EFCCC and their regional counter- parts | Devel- opment partners | 150 000.00 |
| Evaluation | Baseline assessment | Assessment report | 2021 | 1 | MOH, MOA, EFCCC, partners | Respective regional counter-parts | 15 000.00 |
| | Midterm evaluation | Evaluation report | 2023 | 1 | MOH, MOA, EFCCC and their | Academia | 25 000.00 |
| | Terminal evaluation | Evaluation report | 2025 | 1 | regional counter- parts, partners | Academia | 40 000.00 |
| Total | | | | | | | 365 000.00 |

5.3 KEY PERFORMANCE INDICATORS

Core indicators have been selected to evaluate whether activities in the coming years are executed as planned and outcomes achieved as anticipated. They will also provide learning on how to improve future activities. Using the following guiding principles, 36 key performance indicators were selected for the monitoring and evaluation of the National Antimicrobial Resistance Prevention and Containment Strategic Plan.

- Relevance: significance of the indicators that measure each component of the plan.
- Feasibility: in terms of cost, time, data collection and capturing the burden.
- Sensitivity: change over two to three years of the reporting period.
- · Consistency with international standards.

Table 15 Key performance indicators

| Indicator | Туре | Baseline 2020 | Yearly Y1 | / targe Y2 | t (2021 Y3 | -2025) Y4 |) Y5 | Data source | Peri- odic- ity | Level of data col- lection |
|--|--------------|------------------|--------------|---------------|------------------------------------|----------------|---------|---|-----------------------|-----------------------------------|
| Objective one: Impeffective behaviou | | | | | | | | | tance t | hrough |
| Number of dissemination events for IEC and BCC materials in the human, animal and environment sectors (1.1) | Out- put | 2 | 4 | 6 | 8 | 10 | 12 | Institutional activities and event reports | Annu- al | Institution (three sectors) |
| Awareness and understanding level increased on antimicrobial resistance among humans, animals and environment health professionals (1.1) | Out- come | NA | | | 5% from the base- line | | 10% | Surveys | 2–3 years | Population |
| Number of media spots dis- seminated to the public (1.1) | Out- put | 2 | 4 | 6 | 8 | 10 | 12 | Institution- al reports | Annu- al | Institution (three sectors) |
| Number of anti- microbial train- ings for media professionals (1.3) | Out- put | 1 | 4 | 6 | 8 | 10 | 12 | Institutional reports | Annu- al | Institution (three sectors) |

| Indicator | Туре | Baseline | Yearly | y targe | et (2021 | -2025) | | Data | Peri- | Level of |
|--|--------------|---|-------------|--------------|--------------|--------------|--------------------|---|--------------|-----------------------------------|
| | | 2020 | Y1 | Y2 | Y3 | Y4 | Y5 | source | odic- ity | data col- lection |
| Number of advo- cacy workshops created on anti- microbial resist- ance for policy- makers (1.4) | Out- put | 0 | 1 | 2 | 3 | 4 | 5 | Institutional reports | Annu- al | Institution (three sectors) |
| Objective two: Str | | | wledg | e and | evider | nce on | antin | nicrobial us | e and r | esistance |
| Number of antimicrobial resistance surveillance sentinel sites employed to detect and report antimicrobial resistance, in human and animal health sectors (2.1) | Out- put | H-9 A-1 | H-12 A-1 | H-16 A-2 | H-19 A-3 | H-22 A-4 | H-25 A-5 | Admin reports | Rou- tine | Institution |
| Percentage of bloodstream infections due to methicillin-resist- ant staphylococ- cus aureus and extended spec- trum beta-lacta- mase E. coli among patients seeking care and blood sampled (2.1) | Out- come | 32.5% for methicil- lin-resist- ant staph- ylococcus aureus, 50% extended spectrum be- ta-lacta- mase E. coli | | | | | 10% | Published surveil- lance reports | 5 years | Institution |
| Number of human, animal and environment labs with a standard quality management system (2.2) | Out- come | H-2 A-1 E-0 | 9 - | 12 - - | 16 - - | 19 - - | H-25 A-2 E-1 | Admin reports | Rou- tine | Institution |
| Number of research studies conducted on prioritized antimicrobial resistance areas (2.3) | Out- put | NA | | 2 | 4 | 7 | 10 | Published literature | Annu- al | NA |

| Indicator | Туре | Baseline 2020 | Yearly Y1 | / targe Y2 | t (2021 Y3 | -2025) Y4 | Y5 | Data source | Peri- odic- ity | Level of data col- lection |
|--|--------------|------------------|--------------|---------------|---------------|--------------|------|-----------------------|-----------------------|----------------------------------|
| Objective three: E health, infection p care | | | | | | | | | | |
| Percentage of facilities adhered with updated infection prevention and control policies, standard protocols and guidelines in human and animal health care (3.1) | Out- come | NA | 5% | 20% | 40% | 60% | 80% | Survey reports | Annu- al | Institution |
| Decreased rate of health care-as- sociated infec- tions (3.2) | Out- come | 39.6% | | 5% | | | 10% | Survey reports | 3-5 years | Institution |
| Percentage of facilities having biosecurity guidelines for animal feed processing, poultry, dairy and beef production (3.3) | Out- put | 0 | | | 30% | | 50% | Survey reports | 2–3 years | Institution |
| Objective four: Op | timize | the use of | antin | | | | | | | th care |
| Percentage of essential antimicrobials and lab supplies included in the Government's long-term procurement list (4.1) | Out- put | - | | 100% | 100% | 100% | 100% | Survey reports | 2–3 years | Institution |
| Number of hazard analysis critical control point inspections conducted on food preparation and dispensing centres (4.4) | Out- put | - | 1 | 2 | 3 | 4 | 5 | Inspection reports | Rou- tine | Institution |

| Indicator | Туре | Baseline | Yearly | v targe | et (2021 | -2025) | | Data | Peri- | Level of |
|---|--------------|----------|--------|---------|----------|--------|------|-----------------------|--------------|----------------------|
| | ,, | 2020 | Y1 | Y2 | Y3 | Y4 | Y5 | source | odic- ity | data col- lection |
| Number of health care facilities implementing an- timicrobial stew- ardship (4.2) | Out- put | 30 | 60 | 75 | 90 | 100 | 150 | Facilities reports | Rou- tine | Institution |
| Availability of updated veterinary standard treatment guidelines at veterinary health facilities (4.3) | Out- put | 0 | 25% | 50% | 80% | 90% | 100% | Admin reports | Rou- tine | Institution |
| Percentage of adherence to standard treat- ment guidelines in hospitals (4.2) | Out- come | NA | | 32 | | | 60 | Survey reports | 2–3 years | Health facilities |
| Number of hospitals conducting hazard analysis critical control point prevalence survey (4.2) | Out- put | 0 | 10 | 20 | 40 | 60 | 90 | Survey reports | Annu- al | Health facilities |
| Number of guide- lines on prudent use of antimicro- bials in animal health sector and food production (4.3) | Out- put | 0 | 2 | | | | | Admin reports | Annu- al | Institution |
| Number of hospitals that generate antibiogram data (4.4) | Out- put | 9 | 12 | 15 | 20 | 25 | 30 | Survey reports | Rou- tine | Health facilities |
| Percentage of health facilities complying with the Rational Med- icine Use Direc- tive (4.5) | Out- come | NA | | | 60 | | 75 | Survey reports | 3–5 years | Health facilities |

| Indicator | Туре | Baseline | Yearly | / targe | t (2021 | -2025) | | Data | Peri- | Level of |
|---|--------------|----------|--------|---------|---------|----------|---------|---------------------|--------------|----------------------|
| | | 2020 | Y1 | Y2 | Y3 | Y4 | Y5 | source | odic- ity | data col- lection |
| Percentage of adherence to waste management standards in manufacturing and food processing plants (4.5) | Out- come | | | | 50 | | 70 | Survey reports | 3-5 years | Manufac- turers |
| Number of train- ings provided for animal owners on withdrawal peri- od and maximum residue limit | Out- put | NA | 5 | 10 | 15 | 20 | 25 | Admin reports | Annu- al | Institution |
| Objective five: Stre | | | blish | partne | erships | , alliar | ices, g | governance | and re | esource |
| Number of advo- cacy workshops conducted to en- gage the private sector on antimi- crobial resistance prevention and containment (5.1) | Out- put | 0 | 2 | 4 | 6 | 8 | 10 | Admin reports | Annu- al | Institution |
| Number of institutions that have incorporated antimicrobial resistance prevention and containment into their approved annual plan (5.2) | Input | 7 | 17 | 25 | | | 189 | Survey reports | Annu- al | Institution |
| Number of identified innovative financing mechanisms for antimicrobial resistance prevention and containment (5.3) | Out- come | 0 | | 1 | | 2 | | Document reviews | 2–3 years | Institution |
| Generated evidence that shows return on investment in antimicrobial resistance prevention and containment in selected institutions (5.3) | Out- put | 0 | | | 1 | | 2 | Study reports | 2-3 years | Institution |

6. RISKS AND MITIGATION





6. RISKS AND MITIGATION

During the implementation of the National Antimicrobial Resistance Prevention and Containment Strategy, the sectors may encounter risks that impede achievement of results. The following table articulates the risks identified through the SWOT analysis and stakeholder analysis and strategies to address or mitigate them.

| S. No | Risk | Mitigation strategy |
|-------|---|---|
| I | COVID-19 and its impacts on the health system (human and animal) and the environment | The MOH, MOA and EFCCC in close collaboration with the Government and different ministries will actively work on the pre- |
| | and the environment | vention and control of COVID-19. As a priority public health concern, its control will be enhanced through implementation of appropriate and effective public health |
| | | measures. In line with the COVID-19 controls, the MOH, the MOA, the EFCCC and other stakeholders will implement the National Antimicrobial Resistance Prevention and Containment strategy by integrating it into COVID-19 activities. |
| 2 | Occurrence of emerging and re-emerging microbial diseases (human and animal) | The MOH and MOA will strengthen the public health (human and animal) emergency management system by improving the capacity for emergency preparedness, prevention, early detection and response of emerging and re-emerging diseases. |
| 3 | Inadequate financial resources and sudden reduction of donor funds (low predictability of external funding due to world economic recession) | The antimicrobial prevention and containment strategy will follow efforts to address the financial gaps. Implementation of innovative domestic financing strategies to mobilize adequate finance domestically will be implemented. |
| | | Public-private partnerships are to be strengthened. |
| 4 | Weak intersectional collaboration | The MOH, MOA and EFCCC will work closely with the Government and other stakeholders to collaborate in addressing the implementation of antimicrobial resistance prevention and containment. |
| 5 | Inadequate private sector involvement | The MOH, MOA and EFCCC will work with other government ministries and agencies, civil society organizations and the private sector to attract investment on antimicrobial resistance prevention and containment and strengthen public–private partnerships. |

REFERENCES

- Alemkere, G (2018). Antibiotic usage in surgical prophylaxis: a prospective observational study in the surgical ward of Nekemte referral hospital. PLoS ONE. doi: 10.1371/journal.pone.0203523.
- Ayalew MB (2017). Self-medication practice in Ethiopia: a systematic review. Patient Prefer Adherence. 11:401-413. doi: 10.2147/PPA.S131496. PMID: 28280312; PMCID: PMC5338978.
- Beyene D, Bitew A, Fantew S, Mihret A, Evans M (2019). Multidrug-resistant profile and prevalence of extended spectrum -lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia. PLoS ONE. 9:e0222911. (https://doi.org/10.1371/journal.pone.0222911).
- Central Statistics Agency (CSA) (2013). Population projection for Ethiopia from 2007–2037. Addis Ababa.
- Eshetie S, Tarekegn F, Moges F, Amsalu A, Birhan W, Huruy K (2016). Methicillin resistant Staphylococcus aureus in Ethiopia: a meta-analysis. BMC Infect Dis. 16(1):689. doi:10.1186/s12879-016-2014-0
- Eshetie S et al. (2017). Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 1:219. doi: 10.1186/s12879-017-2323-y. PMID: 28320336; PMCID: PMC5360058.
- Ethiopian Food and Drug Authority (EFDA) (2011). National strategic framework for the prevention and containment of antimicrobials resistance. Addis Ababa.
- Ethiopian Food and Drug Authority (EFDA) (2015). Strategy for the prevention and containment of antimicrobial resistance for Ethiopia, Second Edition, 2015–2020. Addis Ababa.
- Ethiopian Public Health Institute (EPHI) (2018). National AMR surveillance annual report 2018–2020. Addis Ababa.
- Ethiopian Public Health Institute (EPHI) (2019). National AMR surveillance Annual Report (2nd Year) September 2018 October 2019. Addis Ababa, https://www.ephi.gov.et/images/files/Final-Annual-report---V.9.-Gebrie-1.pdf
- Federal Democratic Republic of Ethiopia (2016). Growth and transformation plan II 2016–2020. Addis Ababa.
- Food and Agriculture Organization of the United Nations (FAO) (2019). The future of livestock in Ethiopia: opportunities and challenges in the face of uncertainty. Rome. Licence: CC BY-NC-SA 3.0 IGO.
- Gebretekle GB et al. (2020) Half of prescribed antibiotics are not needed: a pharmacist-led antimicrobial stewardship intervention and clinical outcomes in a referral hospital in Ethiopia. Frontiers in Public Health. doi:10.3389/fpubh.2020.00109.
- Girum T, Muktar E, Lentiro K, Wondiye H, Shewangizaw M (2018). Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med Vaccines. 4:5. doi:10.1186/s40794-018-0065-5.
- Gutema G et al. (2018). Multiple challenges of antibiotic use in a large hospital in Ethiopia: a ward-specific study showing high rates of hospital-acquired infections and ineffective prophylaxis. BMC Health Services Research. doi: 10.1186/s12913-018-3107-9.

- Hailu T, Ejigu E, Geremew E, Adinew A (2014). Auditable pharmaceutical transactions and services: findings of the baseline assessment at federal, Addis Ababa and teaching hospitals. Addis Ababa and Arlington, VA: Systems for Improved Access to Pharmaceuticals and Services Program and Management Sciences for Health.
- Hussen S, Mulatu G, Yohannes Kassa Z (2019). Prevalence of Shigella species and its drug resistance pattern in Ethiopia: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 18(1):22. doi: 10.1186/s12941-019-0321-1. PMID: 31288806; PMCID: PMC6617577.
- International Food Policy Research Institute (IFPRI) (2011). The Ethiopia Strategy Support Program II (ESSP II): crop production in Ethiopia: regional patterns and trends. Addis Ababa.
- Kebede AH et al. (2014). The first population-based national tuberculosis prevalence survey in Ethiopia, 2010–2011. Int J Tuberc Lung Dis. 18(6):635-9. doi:10.5588/ijtld.13.0417. PMID: 24903931.
- Melese A, Genet C, Andualem T (2020). Prevalence of Vancomycin-resistant enterococci (VRE) in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 20(1):124. doi:10.1186/s12879-020-4833-2.
- Ministry of Agriculture (MOA) and International Livestock Research Institute (ILRI) (2013). Animal health strategy and vision for Ethiopia. Addis Ababa.
- Ministry of Education (MOE) (2020). Education statistics annual abstract, September 2019– March 2020. Addis Ababa.
- Ministry of Health (2019). Assessment of stakeholders' engagement status on antimicrobial resistance prevention and containment. Addis Ababa. Unpublished.
- Ministry of Agriculture (MOA) and International Livestock Research Institute (ILRI) (2013). Animal health strategy and vision for Ethiopia. Addis Ababa.
- Ministry of Education (MOE) (2020). Education statistics annual abstract, September 2019– March 2020. Addis Ababa.
- Ministry of Health (2019). Assessment of stakeholders' engagement status on antimicrobial resistance prevention and containment. Addis Ababa. Unpublished.
- Ministry of Health (MOH) (2020a). Health sector transformation plan II, 2020/21-2024/25. Addis Ababa.
- Ministry of Health (MOH) (2020b). Rapid assessment on implementation status of antimicrobial resistance prevention and containment strategy and plan of action 2015–2020 at regional level. Addis Ababa. Unpublished.
- Ministry of Health (MOH) (2020c). Pharmacy services, pharmaceutical supply chain performance and medical equipment management in public hospitals: a monitoring and evaluation baseline survey. Addis Ababa. Unpublished.
- National Animal Health Diagnosis and Investigation Center (NAHDIC) (2019). Integrated national antimicrobial resistance and residue surveillance plan in animal health, plant, food safety and environmental sector of Ethiopia, 2019–2023. Addis Ababa.
- O'Neill J (2014). Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on antimicrobial resistance. (https://wellcomecollection.org/works/rdpck35v).
- O'Neill J (2016). Tackling drug-resistant infections globally: final report and recommendations.

- May 2016. (https://amr-review.org/sites/default/files/160518_Final% 20paper_with%20cover. pdf).
- Sisay M et al. (2018). Resistance profile of clinically relevant bacterial isolates against fluoro-quinolone in Ethiopia: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 19(1):86. doi: 10.1186/s40360-018-0274-6. PMID: 30541613; PMCID: PMC6292079.
- Sisay M, Mengistu G, Edessa D (2018). Epidemiology of self-medication in Ethiopia: a systematic review and meta-analysis of observational studies. BMC Pharmacol Toxicol. 19:56. (https://doi.org/10.1186/s40360-018-0248-8).
- Tadesse G (2014). A meta-analysis of the proportion of antimicrobial resistant human salmonella isolates in Ethiopia. BMC Pharmacol Toxicol. 15:51. doi: 10.1186/2050-6511-15-51. PMID: 25213011; PMCID: PMC4164349.
- Tuem KB, Gebre AK, Atey TM, Bitew H, Yimer EM and Berhe DF (2018). Drug resistance patterns of Escherichia coli in Ethiopia: a meta-analysis. Biomed Res Int. 4536905. doi:10.1155/2018/4536905. PMID: 29854757; PMCID: PMC5960519.
- Tufa TB et al. (2020). High rate of extended-spectrum beta-lactamase-producing gram-negative
 infections and associated mortality in Ethiopia: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 9:128 (https://doi.org/10.1186/s13756-020-00782-x).
- World Bank (2019). GDP per capita (current US\$) Ethiopia. Washington, DC. (https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=ET).
- World Health Organization (WHO) (2015). Global action plan on antimicrobial resistance. Geneva.
- Zeru H, Gemechu A, Andualem T, Seid H and Mengesha F (2019). Awareness of veterinary drug retail outlets on antimicrobial resistance and its containment strategy in Ethiopia. Pharmacovigil and Pharmacoepi. 2: 913.

ANNEX

TERMS OF REFERENCES FOR ANTIMICROBIAL RESISTANCE MULTISECTOR GOVERNANCE STRUCTURE

1.TERMS OF REFERENCE NATIONAL INTERMINISTERIAL COMMITTEE FORANTIMICROBIAL RESISTANCE PREVENTION AND CONTAINMENT

Introduction

Antimicrobials include antibiotics, antifungals, antivirals and anti-protozoal. They are critical to human, animal and plant health and the environment and to a country's development and security. Despite the innovation of many antimicrobials in the world, the emergence of drug-resistant bacterial strains has become a top global public health agenda priority. Antimicrobials used and misused for human and animal health care can be found in food as residues and also are excreted unchanged into the environment (water and soil) as contaminants creating selection pressure on microorganisms.

Antimicrobial resistance occurs when microorganisms change in a way that reduces or eliminates the effectiveness of antimicrobials that were used to cure or prevent infections. By so doing, the microorganisms continue to survive and multiply, with their presence causing more harm. In human and animal health, it implies that life-threatening infections that were previously manageable are poised to be untreatable because of antimicrobial resistance. This will lead to high morbidity and mortality in human diseases, reduction in agricultural output and related livelihood and economy-wide impacts. It will increase poverty and render achievement of the Sustainable Development Goals difficult if not impossible. If nothing is done to stem these threats, it could force up to 24 million people into extreme poverty by 2030. By 2050 the global economy may lose more than \$100 trillion dollars annually because of antimicrobial resistance and the reduction in GDP by an estimated global average of 3.8% high for low-income countries. More people will go into poverty due to antimicrobial resistance.

Resistant microorganisms have no borders, making it truly a global problem that requires One Health solutions. Coordinated action is required to minimize the emergence and spread of antimicrobial resistance. Members of the public, of the scientific and medical communities, of the national and regional authorities as well as the international community can and should contribute to the solutions.

One of the major objectives of the Global Health Security Agenda is to accelerate progress towards a world safe and secure from infectious disease threats. The Global Health Security Agenda has developed 11 "action packages" that are implemented under three titles: Prevent, Detect and Respond. The action packages concept was developed to facilitate regional and global collaboration towards specific Global Health Security Agenda objectives and targets. Antimicrobial resistance is one of the 11 action packages requiring national multisector and international collaboration.

Tackling the global spread of antimicrobial resistance is also a high priority agenda for the World Health Organization (WHO), the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (OIE) and their member countries. WHO, FAO and OIE launched a Global Strategy and Plan of Action for Containment of Antimicrobial Resistance that follows the One-Health approach. Countries have developed national strategies and action plans so that they can prevent and manage antimicrobial resistance across multiple sectors.

In line with the WHO Global Strategy and Plan of Action, Ethiopia has committed to develop a National Action Plan on Antimicrobial Resistance and mobilize the necessary resources. Under the coordination and leadership of the Ethiopian Food and Drug Authority, a National Antimicrobial Resistance Advisory Committee composed of multiple stakeholders has been established to oversee the country's antimicrobial resistance prevention and containment activities.

Recognizing that bringing antimicrobial resistance under control requires consolidated, concerted action by multiple stakeholders, the Ministry of Health, in collaboration with the Ministry of Agriculture and the Ethiopian Forestry, Environment and Climate change Commission, has taken the initiative leveraging on the gains already made by strengthening and restructuring the country's efforts to contain and prevent antimicrobial resistance. A federal multisector governance mechanism is to be established to serve as the central intervention around which all the antimicrobial resistance-related activities can be effectively coordinated in each of the relevant sectors. This will ensure a systematic and comprehensive approach that would be broad enough to address all five strategic objectives of the antimicrobial resistance action plan, prioritizing activities in a step-wise approach.

The antimicrobial resistance governance mechanism for Ethiopia will comprise a high-level National Inter-Ministerial Committee, the national antimicrobial resistance focal point (AMR secretariat), the National Antimicrobial Resistance Advisory Committee and multisector technical working groups that will address the objectives of the national action plan.

Given the ultimate goal of antimicrobial resistance containment efforts that are geared to improve health outcomes, the National Interministerial Committee will be formed to provide necessary political commitment and support and avail of financial and human resources for national antimicrobial resistance containment and prevention efforts.

Objective

The main objective of the National Interministerial Committee is to provide necessary political commitment and authority for the coordination and implementation of country's antimicrobial resistance containment and prevention efforts.

Roles and responsibilities

- Political support: As antimicrobial resistance has an impact on all human and veterinary medical activities as well as on the environment, which justifies a multisector approach based on the One Health concept, advocacy on the risk of antibiotic resistance and to the proper use of antibiotics as a public health priority, the National Interministerial Committee will sustain political decisions and support to control antimicrobial resistance.
- **Leadership**: The National Interministerial Committee will set joint leadership with other relevant ministries that might require oversight from a specified authority.
- **Policy direction**: The National Interministerial Committee will set strategic and policy directions that support implementation of the antimicrobial resistance prevention and containment activities.
- **Dedicated funds**: The availability of dedicated funds will increase the operational effectiveness of the program. Hence, the National Interministerial Committee will solicit and secure funds to ensure political "ownership" and increase the likelihood of programme sustainability.
- Authority to act: The National Interministerial Committee will give sufficient authority to ensure that
 its decisions and plans are implemented.
- Coordination and collaboration: Addressing the growing threat of antimicrobial resistance is a shared responsibility that requires multisector collaboration. The National Interministerial Committee will:

- · Work with other government offices, domestic and international partners on reducing the public
- health risks and impacts of antimicrobial resistance.
- Support and collaboratively evaluate the performance of regional state and city administrations in cascaded implementation of the national strategy and plan of action on antimicrobial resistance prevention and containment.

Membership

The National Interministerial Committee will have the following members:

- 1. Ministry of Health Chair
- 2. Ministry of Agriculture Co-chair
- 3. Ministry of Water, Irrigation and Energy –member
- 4. Ministry of Education member
- 5. Ministry of Science and Higher Education -member
- 6. Ministry of Innovation and Technology -member
- 7. Ministry of Finance -member
- 8. Ministry of Women, Children and Youth -member

The secretary of the National Interministerial Committee will be an adviser to the Minister of Health.

Meetings

• The National Interministerial Committee will meet biannually, using the existing platforms that accommodated all its members. Extraordinary meetings can be arranged when necessary.

Accountability

• The National Interministerial Committee will be accountable to the Council of Ministers.

Working procedure

- The National Interministerial Committee will have a chair and co-chair, members and secretary.
- The meeting agenda would be prepared by chair of the National Antimicrobial Resistance Advisory Committee and be communicated to the organizers via email and phone at least two weeks before the meeting date.
- The National Interministerial Committee will communicate action points (reports and recommendations) and correspondence, reports and decisions regularly to the Council of Ministers and member organizations.
- Members of National Antimicrobial Resistance Advisory Committee will attend the Inter-Ministerial Committee meetings.

Terms of service

 Membership is for unlimited period, except for ministers who are leaving or shifted from the former organization where they are represented.

2. TERMS OF REFERENCE NATIONAL ADVISORY COMMITTE FOR ANTIMICROBIAL RESISTANCE PREVENTION AND CONTAINMENT

Introduction

Resistance to the effects of antimicrobial drugs is a serious problem in the world. Antimicrobial resistance occurs naturally over time, usually through genetic changes. However, the misuse and overuse of antimicrobials is accelerating this process. Antimicrobial resistance costs lives and money and threatens our ability to treat infections in humans and animals. Drug resistance has become a global public health crisis. Because of its effect on food production, economy and security, antimicrobial resistance is also considered a threat to health, national security and the economy. If nothing is done to stem this crisis, it could force up to 24 million people into extreme poverty by 2030.

Coordinated action is required to minimize the emergence and spread of antimicrobial resistance. Members of the public, of the scientific and medical communities, local and national authorities as well as the international community can and should contribute to the solutions. Several efforts have been made to curb the multidimensional challenges of antimicrobial resistance. Tackling the global spread of antimicrobial resistance is a high priority for the World Health Organization (WHO), the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and their member countries. The three organizations launched the Global Strategy and Plan of Action for Containment of Antimicrobial Resistance. Countries are developing a national action plan to prevent and manage antimicrobial resistance across multiple sectors following the One Health approach.

The effective control of infectious diseases in Ethiopia is compromised by the increasing trends of microorganisms' resistance to the antimicrobials use in human and animal health care system. The emergence and spread of resistant strains have called for swift and concerted efforts of various agencies. The task needs to be overseen by high-level officials of the Ministry of Health, the Ministry of Agriculture and the Forestry, Environment and Climate Change Commission because the outcomes of the overall activities will affect the quality of health services of human, animal and plant as well as food production and economy in the country.

In line with the WHO Global Strategy and Plan of Action, Ethiopia has developed a national plan on antimicrobial resistance and mobilized the necessary resources. Under the coordination and leadership of the Ethiopian Food and Drug Authority, a national advisory committee composed of multiple stakeholders has been established to oversee the country's antimicrobial resistance prevention and containment activities.

Recognizing that bringing antimicrobial resistance under control requires consolidated, concerted action by multiple stakeholders, the Ministry of Health, the Ministry of Agriculture and the Ethiopian Forestry, Environment and Climate Change Commission are leveraging the gains already made by strengthening and restructuring the country's efforts to contain and prevent antimicrobial resistance. Having a national multisector governance mechanism will serve as the central intervention around which all the antimicrobial resistance-related activities can be effectively coordinated in each of the relevant sectors. This will ensure a systematic and comprehensive approach. The scope should be broad enough to address all five objectives of the Global Strategy, prioritizing activities in a step-wise approach.

The governance mechanism will encompass a high-level National Interministerial Committee, an antimicrobial resistance focal point (the AMR secretariat), the National Antimicrobial Resistance Advisory Committee and multisector technical working groups that will address the respective strategic objectives of the national action plan.

In accordance with the governance framework, the National Antimicrobial Resistance Advisory Committee involving a wide range of partners will be reorganized to enhance multisector collaborations in addressing the risk of antimicrobial resistance and minimize its impact on human and animal health in the country.

Objective

The main objective of the National Antimicrobial Resistance Advisory Committee is to oversee and coordinate all antimicrobial resistance-related activities in all sectors to ensure systematic and comprehensive approaches accorded with defined antimicrobial resistance-related goals and with the global action plan for antimicrobial resistance. The scope should be broad enough to address all five strategic objectives of the national action plan, prioritizing activities in a step-wise approach.

Roles and responsibilities

- Plan and set an overall direction for antimicrobial resistance control and prevention in Ethiopia and ensure that major goals and timelines are achieved.
- Provide platform for programme planning and implementation through a supporting structure comprising
 of technical working groups for individual strategic objectives.
- Facilitate and coordinate efforts to contain and reduce the threat of antimicrobial resistance at all levels.
- · Collaborate with internal and external agencies and organizations.
- Provide a structure for information-sharing to mutually reinforce activities among sectors.
- Ensure adequate integration of antimicrobial resistance containment efforts into the existing health system, public health and disease-specific programmes, animal health and food production sector and other environmental initiatives.
- Advocate for prevention and containment of antimicrobial resistance.
- Monitor and evaluate the existing technical working groups and their respective activities in relation to the national action plan.
- Collaboratively work with and support regional and city administration Antimicrobial Resistance Advisory Committees.
- Coordinate joint monitoring and evaluation of implementation and results and achievements of the National Antimicrobial Resistance Prevention and Containment Strategy and Plan of Action.

Membership

The National Antimicrobial Resistance Advisory Committee is to be composed of officially delegated members representing the relevant sectors, notably human health, animal health, agriculture and the environment. Representatives should be given sufficient authority by their institutions to make decisions. Hence, the following institutions are members of the National Antimicrobial Resistance Advisory Committee.

| | Organization | | | Remark | | |
|---|--|--|---------------------|-----------|--|--|
| Go | vernment organizations | | | | | |
| 1 | Ministry of Health, Medical Service Director Genera | | | Chair | | |
| 2 | Veterinary Drug and Feed Administration and Contr | | | Co-chair | | |
| 3 | Ministry of Agriculture, Veterinary Public Health Dir | | | | | |
| 4 | Ministry of Agriculture, Plant Health Directorate | | | | | |
| 5 | Ministry of Health, Clinical Service Directorate | | | | | |
| 6 | Ministry of Health, Deliverology Unit | | | | | |
| 7 | Water, Environment, Forestry and Climate Change (| Commission | | | | |
| 8 | Ministry of Science and Higher Education | | | | | |
| 9 | Ethiopian Food and Drug Authority | | | | | |
| 10 | Ethiopian Public Health Institute | | | | | |
| 11 | Armaour Hansen Research Institute | | | | | |
| 12 | Ethiopian Pharmaceutical Supply Agency | | | | | |
| 13 | National Animal Health Diagnostic and Investigation | n Centre | | | | |
| 14 | National Veterinary Institute | | | | | |
| | Communication and Broadcast Authority, Ministry of Health, Public Relations Directorate | | | | | |
| 15 | Communication and Broadcast Authority, Ministry of | of Health, Public Relat | ions Directorate | 9 | | |
| 16 | Ministry of Health, Pharmaceuticals and Medical Eq | uipment Directorate | ions Directorate | Secretary | | |
| 16 | Ministry of Health, Pharmaceuticals and Medical Equations of the section of the s | uipment Directorate | ions Directorate | | | |
| Rep dire | Ministry of Health, Pharmaceuticals and Medical Equations presentatives from professional association ectors Ethiopian Medical Association | uipment Directorate | ions Directorate | | | |
| Rep direct | Ministry of Health, Pharmaceuticals and Medical Equations oresentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association | uipment Directorate | ions Directorate | | | |
| 16 Rep direction 1 2 3 | Ministry of Health, Pharmaceuticals and Medical Equations presentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association | uipment Directorate | ions Directorate | | | |
| 16 Rep direction 1 2 3 4 | Ministry of Health, Pharmaceuticals and Medical Equations Presentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association | uipment Directorate | ions Directorate | | | |
| 16 Rep direction 1 2 3 4 5 | Ministry of Health, Pharmaceuticals and Medical Equations Presentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association | uipment Directorate | ions Directorate | | | |
| 16 Rep direction 1 2 3 4 5 6 | Ministry of Health, Pharmaceuticals and Medical Equations Presentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association Ethiopian Medical Laboratory Association | ns – executive | ions Directorate | | | |
| Rep direction 1 2 3 4 5 6 7 7 | Ministry of Health, Pharmaceuticals and Medical Equations Percentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association Ethiopian Medical Laboratory Association Ethiopian Private Health Facilities Employers Association | ns – executive | | | | |
| Rep direction 1 2 3 4 5 6 7 7 | Ministry of Health, Pharmaceuticals and Medical Equations Presentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association Ethiopian Medical Laboratory Association Ethiopian Private Health Facilities Employers Association Ethiopian Private Health Facilities Employers Association | ns – executive | | | | |
| Rep direction 1 2 3 4 5 6 7 Rep 1 | Ministry of Health, Pharmaceuticals and Medical Equations Presentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association Ethiopian Medical Laboratory Association Ethiopian Private Health Facilities Employers Association | iation ons – focal perso | | | | |
| Rep direction 1 2 3 4 5 6 7 Rep 1 2 | Ministry of Health, Pharmaceuticals and Medical Equations Presentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association Ethiopian Medical Laboratory Association Ethiopian Private Health Facilities Employers Association Ethiopian Private Health Organization | iation ons – focal perso | | | | |
| Rep direction 1 2 3 4 5 6 7 Rep 1 | Ministry of Health, Pharmaceuticals and Medical Equations Presentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association Ethiopian Medical Laboratory Association Ethiopian Private Health Facilities Employers Association | iation ons – focal perso | | | | |
| Rep direction 1 2 3 4 5 6 7 Rep 1 2 3 4 4 | Ministry of Health, Pharmaceuticals and Medical Equations Persentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association Ethiopian Medical Laboratory Association Ethiopian Private Health Facilities Employers Association | iation ons – focal perso | ons | Secretary | | |
| Rep direction 1 2 3 4 5 6 7 Rep 1 2 3 4 4 | Ministry of Health, Pharmaceuticals and Medical Educators Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association Ethiopian Medical Laboratory Association Ethiopian Private Health Facilities Employers Association Food and Agriculture Organization of the United Na United States Agency for International Development Africa Centres for Disease Control and Prevention Presentatives from development partners - | iation ons – focal perso tions t | ons tors and foc | Secretary | | |
| Rep direction 1 2 3 4 5 6 7 Rep 1 2 3 4 4 | Ministry of Health, Pharmaceuticals and Medical Equations Persentatives from professional association ectors Ethiopian Medical Association Ethiopian Veterinary Association Ethiopian Pharmacy Association Ethiopian Public Health Association Ethiopian Nurse Association Ethiopian Medical Laboratory Association Ethiopian Private Health Facilities Employers Association | iation ons – focal perso tions t executive directorate | ons tors and foc | Secretary | | |

Meetings

The National Antimicrobial Resistance Advisory Committee will have a regular meeting schedule every two months. Extraordinary meetings can be arranged when necessary.

Accountability

The National Antimicrobial Resistance Advisory Committee is accountable to the National Interministerial Committee.

Working procedure

- The National Antimicrobial Resistance Advisory Committee will have a permanent chair and co-chair, member and secretary.
- The venue will be at the Ministry of Health's meeting hall, unless members are informed to the contrary. The secretariat shall notify members of the venue of the meetings when communicating the agenda.
- Meeting agenda would be prepared jointly by the chairperson and secretary and be communicated to members via email and phone at least seven days before the meeting date.
- The quorum shall be the chairman, co-chairman, secretary and representatives from 50% plus one of the members.
- Minutes will be recorded by secretary and officially distributed to members through email within a week time after meetings occur. The minutes should be kept by the secretary and copy should be maintained in records at the Ministry of Health and offices for further references.
- All members should attend all meetings regularly in person or send a delegate, when necessary.
- Absenteeism without notifying the chair (co-chair) or secretary is unacceptable.
- If a member is absent for more than three consecutive meetings, an official reminder will be sent to them with a copy to their office.
- If a member is leaving their organization, the organization is required to designate a successor.
- The National Antimicrobial Resistance Advisory Committee will communicate action points (correspondence, reports and decisions) regularly to member organizations.

Terms of service

• Membership is for unlimited period, except for persons who are leaving their organization.

3. TERMS OF REFERENCE NATIONAL ANTIMICROBIAL RESISTANCE PREVENTION AND CONTAINMENT TECHNICAL WORKING GROUPS

Introduction

During the past century, discoveries of microorganisms as causes of infections and antibiotics as effective therapeutic agents have contributed to significant gains in public health in many parts of the world.

Antimicrobials, which includes antibiotics, antifungals, antivirals and anti-protozoal, are critical to human, animal and plant health, the environment, national development and security. Despite the innovation of many antimicrobials in the world, the emergence of drug-resistant bacterial strains has become high on the global public health agenda. Antimicrobials used and misused by humans and animals can be found in food as residues and also are excreted unchanged to the environment (water and soil) as contaminants, creating selection pressure on microorganisms. Antimicrobial resistance occurs when microorganisms change, which reduces or eliminates the effectiveness of the antimicrobials that were used to cure or prevent infections. By so doing, the microorganisms continue to survive and multiply, even in their presence, causing more harm. In human and animal health, it implies that life-threatening infections that were previously manageable are poised to be untreatable. Antimicrobial resistance leads to high morbidity and mortality in human diseases, reduction in agricultural output and related livelihood and economy-wide impacts. It contributes to poverty and to making achievement of the Sustainable Development Goals difficult if not impossible. Without action now, the global economy may lose more than \$100 trillion dollars annually by 2050 due to antimicrobial resistance and associated GDP reductions by a global average of 3.8%, which is high for low-income countries. Many people may fall back into poverty due to antimicrobial resistance. Resistant microorganisms have no borders, making it truly a global problem that requires One Health solutions.

Tackling the global spread of antimicrobial resistance is a high priority for the World Health Organization (WHO), the Food and Agriculture Organization of the United Nations and the World Organization for Animal Health and their member countries. In collaboration, the three organizations launched the Global Strategy and Plan of Action for Containment of Antimicrobial Resistance. Countries have developed national strategies and action plans so that they can better prevent and manage antimicrobial resistance across multiple sectors. In line with the WHO Global Strategy and Plan of Action, Ethiopia has developed a national plan of action on antimicrobial resistance and mobilized the necessary resources. The second five-year (2015–2020) strategy to prevent and contain antimicrobial resistance and respective action plan was developed in 2015 with five objectives:

- Raise awareness and understanding and improve education on antimicrobial use, resistance prevention and containment through effective communication and training.
- Strengthen the knowledge and evidence on antimicrobial use and resistance through One Health surveillance and research.
- Improve infection prevention and contain the spread of resistant microorganisms across human and animal communities and health care settings through individual and environmental sanitation, hygiene and infection prevention measures.
- Optimize the use of antimicrobials in human and animal health through effective stewardship practices.
- Strengthen and establish federal alliances and partnerships, management and governance arrangements and resource mobilization for the prevention and containment of antimicrobial resistance at all levels.

Recognizing that bringing antimicrobial resistance under control requires consolidated, concerted action by multiple stakeholders, the Ministry of Health, in collaboration with the Ministry of Agriculture and the Forestry, Environment and Climate Change Commission, has taken the initiative to leverage the gains already made and to thus strengthen and restructure the country's efforts to contain and prevent antimicrobial resistance.

In accordance with the country's governance mechanism for the multisector national antimicrobial resistance prevention and containment activities, technical working groups are tasked to provide technical oversight and guidance to implement and monitor the five objectives of the national action plan. The technical working groups are mandated to provide technical input and conduct situation analyses under the guidance of the National Antimicrobial Resistance Advisory Committee.

The terms of reference of the technical working group were established by the National Antimicrobial Resistance Advisory Committee, providing specific scope, roles and responsibilities. The groups will be task-specific and focused on areas that the coordinating group has determined to be of particular focus for the country. Depending on the purpose, scope and tasks of the technical working group, membership may come from any of the relevant technical specialties. These may include experts from such areas as infectious diseases, microbiology, infection prevention and control, social health, food and drug regulation, surveillance system expertise, environment and others. The terms of reference should guide the function of the national antimicrobial resistance prevention and containment technical working groups.

Objective

The objective of establishing a technical working group is to have an active technical role in the implementation of the National Antimicrobial Resistance Prevention and Containment Action Plan. Each technical working group, as a team of experts, will be proactive in providing technical input, conducting situation analyses, monitoring and evaluating and recommending revision of the national action plan.

Roles and responsibilities

The roles and responsibilities of each technical working group may depend on the scope of implementation of the strategic objectives and action plans. However, each technical working group will have the following roles and responsibilities in common.

- Operationalize the national action plan under their respective strategic objectives.
- Prepare annual work plan as per the national action plan.
- Collaborate with the National Antimicrobial Resistance Advisory Committee in formulation and revision
 of the national action plan.
- Report to the National Antimicrobial Resistance Advisory Committee on the progress to the implementation of the respective strategic objective.
- Provide updates of ongoing activities and provide technical advice to the National Antimicrobial Resistance Advisory Committee or to the national antimicrobial resistance focal point (the AMR secretariat).
- Work closely with relevant sectors in the implementation of the respective strategic objective to identify challenges, gaps and opportunities.
- Ensure regular data collection and documentation.
- Develop monitoring tools for the performance of implementation of the respective strategic objective.
- Undertake supportive supervision to assess the implementation process.

 Coordinate and participate in selected activities, and build a sustained partnership between implementing sectors.

Membership

Under the leadership of the chairperson of each technical working group who would be an assigned member of the National Antimicrobial Resistance Advisory Committee representing the relevant sectors to the specific activities, membership of technical working groups will comprise relevant technical specialties from relevant sector organizations, partners and associations. Each technical working group shall comprise representatives of the following member organizations.

Technical working group members

| Technical working groups | Member organizations |
|-----------------------------|---|
| Technical working group | Ministry of Health, Public Relations Directorate – Chair |
| for education and awareness | Ministry of Agriculture, Public Relations Directorate |
| 11633 | Ministry of Education, Public Relations Directorate |
| | Ethiopian Food and Drug Authority, Public Relations Directorate |
| | Veterinary Drug and Feed Administration and Control Authority, Public Relations Directorate |
| | Environment, Forestry and Climate Change Commission, Public Relations Directorate |
| | Ministry of Health, Planning, Monitoring and Evaluation Directrate |
| | Ministry of Health, Clinical Service Directorate |
| | Ethiopian Medical Association |
| | Ethiopian Veterinary Association |
| | Ethiopian Pharmacy Association |
| | Ethiopian Public Health Association |
| | Ethiopian Nurse Association |
| | Ethiopian Medical Laboratory Association |
| | Private Health Facility Association |
| | World Health Organization |
| | Food and Agriculture Organization of the United Nations |
| | USAID Global Health Supply Chain Program's Procurement and Supply Management |
| | USAID Medicine, Technology and Pharmaceutical Service |

| Technical working group | Ministry of Health, Clinical Service Directorate – Chair |
|--------------------------------------|--|
| for infection prevention and hygiene | Ministry of Health, Quality Directorate |
| | Ministry of Health, Hygiene and Environmental Health Directorate |
| | Ministry of Health, Disease Prevention and Control Directorate |
| | Ministry of Agriculture, Veterinary Public Health Directorate |
| | Ministry of Agriculture, Plant Health Directorate |
| | Ministry of Water, Irrigation and Energy |
| | Environment, Forest and Climate Change Commission |
| | Ethiopian Food and Drug Authority |
| | Veterinary Drug and Feed Administration and Control Authority |
| | Ethiopian Pharmaceutical Supply Agency |
| | Ethiopian Nurse Association |
| | Africa Centres for Disease Control and Prevention |
| | Food and Agriculture Organization of the United Nations |
| | Infectious Disease Detection and Surveillance Project |
| | United Nations Children's Fund |
| | USAID Medicine, Technology and Pharmaceutical Service |
| | World Health Organization |
| Technical working group | Ethiopian Public Health Institute – Chair |
| for surveillance and re- | Armaour Hansen Research Institute |
| search | Ethiopian Food and Drug Authority |
| | Veterinary Drug and Feed Administration and Control Authority |
| | Ethiopian Pharmaceutical Supply Agency |
| | National Animal Health Diagnostic and Investigation Centre |
| | National Veterinary Institute |
| | Addis Ababa University |
| | St Paul Hospital Millennium Medical College |
| | Infectious Disease Detection and Surveillance Project |
| | |

· Ethiopian Medical Laboratory Association

·World Health Organization

·Africa Centres for Disease Control and Prevention

 $\cdot \, Food \, and \, Agriculture \, \, Organization \, \, of \, the \, \, United \, \, Nations \, \,$

| Technical working group for antimicrobial steward- | \bullet $$ $$ \cdot Ministry of Health, Planning, Monitoring and Evaluation Directorate Chair |
|--|--|
| ship | Ethiopian Food and Drug Authority |
| | Ministry of Health, Clinical Service Directorate |
| | Pharmaceuticals Supply Agency |
| | Ethiopian Public Health Institute |
| | Armaour Hanssen Research Institute |
| | Tikur Anbessa Specialized Hospital |
| | St Paul Millennium Medical College Hospital |
| | • · St Peter Hospital |
| | • · Zewditu Memorial Hospital |
| | Ethiopian Medical Association |
| | Ethiopian Pharmacy Association |
| | World Health Organization |
| | Food and Agriculture Organization of the United Nations |
| | USAID Global Health Supply Chain Program's Procurement and Supply Management |
| | USAID Medicine, Technology and Pharmaceutical Service |
| Technical working group | Ministry of Health, Resource Mobilization Directorate – Chair |
| for resource mobilization for antimicrobial resistance | Ministry of Agriculture, Resource Mobilization Directorate |
| Tot antimicropial resistance | Ministry of Education, Resource Mobilization Directorate |
| | Environment, Forest and Climate Commission, Resource Mobilization Directorate |

Technical working group for regulations and pharmacovigilance

- Ethiopian Food and Drug Authority Chair
- Ethiopian Food and Drug Authority, Product Safety Directorate
- Ethiopian Food and Drug Authority, Medicines Registration and Licensing Directorate
- Ethiopian Food and Drug Authority, Medicines Facility Inspection Directorate
- Veterinary Drug and Feed Administration and Control Authority
- National Animal Health, Diagnostic and Investigation Centre
- Ministry of Health, Planning, Monitoring and Evaluation Directorate
- Ministry of Health Regulatory
- Addis Ababa Regulatory (Food, Medicine and Healthcare Administration and Control Authority)
- Customs Authority and Commission
- Ethiopian Public Health Association
- World Health Organization
- United States Agency for International Development
- United States Pharmacopeia, Pharmaceutical Quality Management
- USAID Medicine, Technology and Pharmaceutical Service
- USAID Global Health Supply Chain Program- Procurement and Supply Management
- Ethiopian Pharmacy Association

Accountability

All antimicrobial resistance technical working groups are accountable to the National Antimicrobial Resistance Advisory Committee.

Working procedure

- Each technical working group shall have a chair and co-chair, member and secretary.
- Each technical working group shall have a regular meeting schedule every month on Friday of the third week of the month starting at 9 a.m. Extraordinary meetings can be arranged when necessary.
- The meeting agenda will be prepared jointly by the chairperson and secretary and be communicated to members via email and phone at least three days before the meeting date.
- The venue for the technical working group meetings would will be the meeting halls of chairs of each technical working group, unless members are informed to the contrary. The secretariat shall notify members of the venue of the meetings when communicating the agenda.
- Minutes will be recorded by the secretary and officially distributed to members through email within a
 week after each meeting. The minutes should be kept by the secretary, and a copy should be maintained
 in the records for further reference.
- At each meeting, minutes of the previous meeting will be endorsed, progress on the decision of previous meetings reported, emerging concerns discussed and recommendations forwarded for high-level decision and action.
- For a meeting that entails a decision, the quorum shall be 50% plus one of the technical working group members, including the chairperson and secretary. The decision will be made on a consensus of the members. If consensus is not reached, the decision shall be made by majority vote. In case of a tie, the chairperson has the deciding vote.
- All members should attend all meetings regularly in person or send a delegate, when necessary.
- If a member is leaving their organization, the organization is required to immediately assign and update their successor.

Each technical working group shall regularly communicate action points (correspondence, reports, decisions and recommendations to the multisector National Antimicrobial Resistance Advisory Committee and respective member organizations.

Terms of service

Membership to the technical working groups is for an unlimited period unless required otherwise by the federal governance mechanism or the federal antimicrobial resistance strategy and action plan.

4. STAKEHOLDER ANALYSIS

| Stakeholders | SO1 | S02 | S03 | SO4 | SO5 |
|--|-----|-----|-----|------------|-----|
| Stakerioliders | 301 | 302 | 303 | 304 | 303 |
| National Antimicrobial Resistance Advisory Committee, One Health Steering Committee | Χ | | | | |
| Academia | | | | Χ | |
| Animal Products, Veterinary Drug and Feed-Quality Assessment Center | | Χ | | | |
| Armauer Hansen Research Institute | | Χ | | | Χ |
| Civil society organizations | Χ | | | | |
| Community, patients, animal owners, clients | Χ | | | | |
| Development partners (local and international) | Χ | Χ | Χ | Χ | Χ |
| Ethiopian Environment and Forest Research Institute | | Χ | | | |
| Ethiopian Food and Drug Authority and its regional counterparts | Χ | Χ | Χ | Χ | Χ |
| Environment, Forestry and Climate Change Commission and its regional counterparts | Χ | Χ | X | Χ | Χ |
| Ethiopian Public Health Institute and its regional counterparts | Χ | Χ | Χ | Χ | Χ |
| Ethiopian Pharmaceutical Supply Agency | | Χ | | Χ | Χ |
| Health Facilities (public and private, human and animal) | Χ | Χ | Χ | Χ | Χ |
| Farm owners | Χ | | | | |
| Farmer-based associations | Χ | | | | |
| Human, veterinary and environmental health professionals | | Χ | | Χ | |
| International organizations (World Health Organization, Food and Agriculture Organization of the United Nations, World Organisation for Animal Health) | Χ | X | X | Χ | Χ |
| Livestock owners | | Χ | | | |
| Media (public and private, print and electronic, owners and professionals) | Χ | | | | Χ |
| Ministry of Agriculture and its regional counterparts | Χ | Χ | Χ | Χ | Χ |
| Ministry of Education | Χ | | Χ | | Χ |
| Ministry of Finance | Χ | | | | Χ |
| Ministry of Health and its regional counterparts | Χ | Χ | Χ | Χ | Χ |
| Ministry of Science and Higher Education | Χ | Χ | | | Χ |
| Ministry of Urban Development and Housing | | | Χ | | |
| Ministry of Water, Irrigation and Electricity | | | Χ | | |
| National Animal Health Diagnostic and Investigation Center and its regional counterparts | | X | Х | Χ | |
| National Vaccine Institute | | Χ | | | |
| Public relation offices of government institutions | Χ | | | | |
| Professional associations (health, agriculture, veterinarian, environment) | Χ | Χ | Χ | Χ | Χ |
| Regional bureaus of health, agriculture and environment | Χ | Χ | Χ | Χ | Χ |
| Technical and vocational education training | Χ | | Χ | | |
| University and research institutions | Χ | Χ | Χ | Χ | Χ |
| Veterinary Drugs and Feed Administration and Control Authority and its regional Counterparts | Χ | Χ | X | Χ | Χ |
| Water and sewerage authorities | | | Χ | | |

5. SUMMARY OF ROLES AND RESPONSIBILITIES OF ANTIMICROBIAL RESISTANCE GOVERNANCE

Interministerial Committee

The Interministerial Committee oversees and implementation of the national strategy, which includes:

- policy direction;
- approval of the national strategic plan;
- approval of budget;
- mobilizing and allocating resources;
- · ensuring sector implementation of the national strategic plan; and
- regularly monitoring and evaluating implementation and achievements.

National AMR secretariat

- Links the national strategic plan at the national and regional state and city administration levels.
- Coordinates cascaded implementation of the national strategic plan at all levels.
- Ensures continuous national, regional state and city administration and international engagement.
- Collects, compiles, prepares and disseminates reports on the implementation and achievements to all stakeholders.
- · Coordinates regular review meeting and monitoring and evaluation platform.
- Engages AMR Advisory Committees and the technical working groups.

National Antimicrobial Resistance Advisory Committee

- Mobilizes human and financial resource to support implementation of the national strategy.
- Submits regular reports and budget proposal on the implementation of the National strategic plan.
- Collaborates and coordinates with the regional state and city administration Antimicrobial Resistance Advisory Committees.
- Regularly reviews, monitors and evaluates cascade implementation of the national AMR strategic plan.
- Oversees and supports the technical working groups.

Regional Antimicrobial Resistance Advisory Committees

- Mobilize human and financial resources to support implementation of the national strategy.
- Submit regular status reports and budgets proposal on the implementation of the regional AMR strategic plan.
- Collaborate with the National Antimicrobial Resistance Advisory Committee.

- Oversee and support the regional technical working groups.
- Regularly review, monitor and evaluate the cascade implementation of the regional strategic plan.

Technical working groups

- Ensure cascaded planning and implementation of the national strategic plan by sector.
- Prepare regular status reports and budget proposal on the implementation of the national strategic plan to the National Antimicrobial Resistance Advisory Committee.
- Regularly review the cascade implementation of the national strategic plan.
- Stakeholders
- Cascade and implement the national strategic plan.
- Submit regular reports and allocate budgets on the implementation of the national strategic plan.
- Regularly review, monitor and evaluate cascade implementation of the national strategic plan.

6. CONTRIBUTORS

Task force members to advise on revisions for the third strategic

plan

| Plati | |
|------------------------|--|
| FULL NAME | ORGANIZATION |
| Yidnekachew Degefaw | Ministry of Health |
| Million Tirfe Megerssa | Ethiopian Food and Drug Authority |
| Getachew Asfaw Tariku | Ministry of Health |
| Dr Hayat Seid Hassen | Veterinary Drug and Feed Administration and Control Authority |
| Wendwosen Shewarega | Ministry of Health |
| Mengsteab W/Aregay | World Health Organization |
| Tenaw Andualem | Food and Agriculture Organization of the United Nations |
| Wondie Alemu | Ethiopian Food and Drug Authority, Procurement and Supply Management |
| DR Meseret Bekele | Ministry of Agriculture |
| Wendimnew Abrie | Environment, Forest and Climate Change Commission |
| Dr Yohannes Demissie | Medicine, Technology and Pharmaceutical Service |
| Workineh Getahun | PMED and USAID-Medicine, Technology and Pharmaceutical Service |
| Yakob Seman | Ministry of Health |
| Regassa Bayisa | Ministry of Health |

Contributors, reviewers and workshop participants

| FULL NAME | ORGANIZATION |
|----------------------|---|
| Abebe kebede | Southern Nations, Nationalities and Peoples' Region |
| Abera Alemu | Dire Dawa Regional Health Bureau |
| Abraham Yirgu | Ethiopian Environment and Forest Research Institute |
| Alemtsehay Adamu | Addis Ababa City Administration Health Bureau |
| Asnakech Alemu | Ethiopian Food and Drug Authority |
| Assefa Gudina | Environment, Forest and Climate Change Commission |
| Atalay Mulu Fentie | Addis Ababa University and Ethiopian Pharmacy Association |
| BekureTsion Gidey | Ethiopian Public Health Institute |
| Belayneh Getachew | National Veterinary Institute |
| Bitseat Shimelis | Ethiopian Food and Drug Authority |
| Dagnew Tadesse | Ministry of Health |
| Deneke Ayele | Ministry of Health |
| Dr Ashenafi G/Mariam | Ministry of Agriculture |
| Dr Ermias Alemu | Ministry of Agriculture |
| Dr Getachew Tesfaye | Armauer Hansen Research Institute |
| Dr Hayat Seid Hassen | Veterinary Drug and Feed Administration and Control Authority |
| Dr Kuastros Mekonnen | National Animal Health Diagnostic and Investigation Center |
| Dr Meseret Bekele | Ministry of Agriculture |
| Dr Nardos Tefera | Veterinary Drug and Feed Administration and Control Authority |

| Dr Wondu Mengesha | Ministry of Agriculture |
|--------------------------|--|
| Dr Yohannes Demissie | USAID Medicines, Technologies and Pharmaceutical Supplies |
| Dr, Nabon Debela | Ministry of Agriculture |
| Dr Alemseged Abdissa | Armauer Hansen Research Institute |
| Dr Asayegn Bekele | Ministry of Agriculture |
| Dr Aynishet Adane | University of Gondar |
| Dr Ermias Alemu | Ministry of Agriculture |
| Dr Gezahagn Mamo | Addis Ababa University Veterinary Faculty |
| Dr Kassu Desta | Ethiopian Medical Laboratory Association |
| Dr Lemma Minda | Ministry of Agriculture |
| Dr Solomon Kebede | Veterinary Drug and Feed Administration and Control Authority |
| Ehitemariam Shambel | Ministry of Health |
| Gebrie Alebachew | Ethiopian Public Health Institute |
| Gemechu Asmera | Jimma University Medical Center |
| Getachew Alemkere Kolech | Addis Ababa University School of Pharmacy |
| Getachew Asfaw Tariku | Ministry of Health |
| Hailu Zeru Berhie | Veterinary Drug and Feed Administration and Control Authority |
| Meaza Debebe | Environment, Forest and Climate Change Commission |
| Mengsteab W/Aregay | World Health Organization |
| Mesfin Mezimur | Orinua Regional Health Bureau |
| Million Tirfe Megerssa | Ethiopian Food and Drug Authority |
| Mintamir mesele | Environment, Forest and Climate Change Commission |
| Moa Abate | Ethiopian Public Health Institute |
| Rogers Kisame | Infectious Disease Detection and Surveillance Project |
| Samuel Aytenfsu Desta | Veterinary Drug and Feed Administration and Control Authority |
| Tenaw Andualem | Food and Agriculture Organization of the United Nations |
| Teshita Shti | Ethiopian Food and Drug Authority |
| Teshome Habtamu | Veterinary Drug and Feed Administration and Control Authority |
| Tigist Abebe | Ministry of Health |
| Tofik Abagaro | Infectious Disease Detection and Surveillance Project |
| Wendimnew Abrie | Environment, Forest and Climate Change Commission |
| Wendwosen Shewarega | Ministry of Health |
| Wondie Alemu | Ethiopian Food and Drug Authority, Procurement and Supply Management |
| Workineh Getahun | USAID-Medicine, Technology and Pharmaceutical Service |
| Yidnekachew Degefaw | Ministry of Health |
| Yimer Mulugeta Aga | Ethiopian Public Health Institute |

Contributors from Medical Service General Directorate

| FULL NAME | ORGANIZATION |
|---------------------|--------------------|
| Yakob Semana | Ministry of Health |
| Regarsa Bayisa | Ministry of Health |
| Mahdi Abdela | Ministry of Health |
| Dr Hillina Tadesse | Ministry of Health |
| Dr Desalew Mekonnen | Ministry of Health |
| Kassu Tolla | Ministry of Health |
| Essayas Mesele | Ministry of Health |
| Abas Hassen | Ministry of Health |
| Dr Hassen Mohammed | Ministry of Health |
| Binyam Kemal | Ministry of Health |
| Fatuma Ebrahim | Ministry of Health |
| Dr Simret Amha | Ministry of Health |



Our time with **ANTIBIOTICS** is running out.

Artitiotics are in danger of losing their effectiveness due to misuse and overuse, and in many cases they aren't even needed.

Always seek the advice of a healthcare professional before taking antibiotics.

